

National Pharmaceutical Pricing Authority

Subject: Minutes of the 54th meeting of the Multidisciplinary Committee of Experts held on 15.09.2023 at 02:30 PM.

54th meeting of the "Multidisciplinary Committee of Experts" was held on 15.09.2023 at 02:30 PM under the convenorship of Shri Sanjay Kumar, Advisor (Cost). The following members attended the meeting: -

1. Shri A.K. Pradhan, Jt. Drugs Controller, CDSCO
2. Dr. J. J. Cherian, Scientist-E (Med), ICMR
3. Dr. Jai Prakash, Sr. Principal Scientific Officer, Indian Pharmacopoeia Commission – Co-opted member

Prof. Y. K. Gupta, Principal Scientific Advisor (Projects), THSTI-DBT, Gol & Ex-HoD, Pharmacology & Dean (Academics), AIIMS, New Delhi – Co-opted member- was unable to attend the meeting. However, he provided his comments on the agenda items through telcon.

The following officers of NPPA attended and presented the cases before the Committee

- a. Ms. Rashmi Tahiliani, Jt. Director (Pricing)
- b. Shri Mahaveer Saini, Deputy Director (Pricing), NPPA

Agenda Item No. 1: Report of the Committee to examine the issue relating to 20% reduction of price of one of the components having lower price while calculating the price of FDCs by the Multidisciplinary Committee of Experts.

Record note of discussion for private circulation.

Agenda Item No. 2: Retail Price fixation of formulation "Formoterol Fumarate Dihydrate 6mcg + Beclomethasone Dipropionate IP 100 mcg Inhaler (MDI) for M/s Cipla Limited in view of DoP's Review Order dated 03.10.2022 – reg.

1. The matter relates to retail price fixation of formulation "Formoterol Fumarate Dihydrate 6mcg + Beclomethasone Dipropionate IP 100 mcg Inhaler (MDI) for M/s Cipla Limited in view of DoP's Review Order dated 03.10.2022.
2. The Committee recalled the deliberations held in 47th meeting of MDC held on 02.12.2022 wherein certain additional documents were sought from the company. A letter dated 27.12.2022 was sent to the company in this respect. M/s Cipla Limited vide letter dated 09.01.2023 requested to allow 1 month time to submit their response. However, no reply was received. Therefore, the matter was again deliberated in 49th meeting of MDC held on 23.02.2023, wherein committee decided to issue final reminder giving one week time to the company to submit the requisite documents. Letter dated 10.03.2023 was sent to M/s Cipla seeking the requisite information within one week. If no reply is received, the matter may be treated as closed.



3. Since no reply was received from M/S Cipla Ltd., the recommendation of the committee for treating the matter as closed was placed in 112th meeting of Authority held on 01.05.2023. However, the Authority referred back the matter to the MDC to provide clear recommendation on the issue.

4. The committee also recalled that while deliberating the matter in the 52nd meeting held on 11.07.2023, it was decided to examine issues raised by M/s CIPLA Ltd. before Hon'ble High Court and during the review. Further, the committee in its 53rd meeting had directed to examine the Writ Petition filed by the company and the counter affidavit filed by NPPA.

5. The Committee also noted that even after 10 months of first discussion held in 47th meeting on 2.12.2022, the company has not furnished the requisite documents.

6. The Committee deliberated in detail regarding the company not obtaining regulatory approval for the 'extra-fine particles of Beclomethasone Dipropionate and Formoterol Fumarate Dehydrate' and the 'digital counter'. However, the request for differential pricing to NPPA used the same arguments. The Committee opined that this inconsistency in the approach of the company seemed deliberate, and was not in public interest.

7. The committee was informed that no counter affidavit has been filed by NPPA. Examination of the issues raised in the WP (C) No. 1709/2020 filed by M/s Cipla Limited in the Hon'ble High Court of Delhi were placed before the Committee as follows:

| Company Contention | Examination |
|--|---|
| <p>The petitioner has challenged on the following three grounds on which MDC recommended the retail price as under:</p> <p>a. Issue of same composition as of M/s Lupin:</p> <p>i. The product has been developed by using extra-fine particles of Beclomethasone Dipropionate and Formoterol Fumarate Dihydrate dissolved in Ethanol and a new propellant HFA 134a (CFC FREE) as a solution formulation. The development involves a highly complex manufacturing process, when compared to the conventional formulation of the competitor.</p> <p>ii. The New HFA134a propellant, a solution formulation was developed by addition of non-volatile component alcohol (ethanol) in which both the active Ingredients beclomethasone</p> | <p>This issue was also raised in the review petition filed to DoP, for which NPPA had given the reply.</p> <p>Further, the matter was also deliberated in detail in 47th MDC meeting held on 02.12.2022, wherein representatives of M/s Cipla Limited requested for incremental price as their product is an innovation and claimed certain therapeutic advantages over the conventional inhaler. Their product is an improved version, which will reach in small airways owing to the reduced particle size. The company also claimed that manufacturing process is highly complex compared to conventional formulation of the competitor (M/S Lupin).</p> <p>The Committee noted the</p> |

Pr

&formoterol dissolve to form a clear solution. This helps to achieve more uniform distribution of the product across the puffs than a typical suspension formulation wherein particles settle rapidly.

- iii. The increased solubility of beclomethasone dipropionate (BDP) in HFA, compared with CFC, resulted in reduction of particle size from 3.5µm to 1.1µm, which can result in an increase in lung deposition and a reduction in oropharyngeal deposition.

Explanation I to Schedule I of DPCO 2013 is extracted herein as under for ease of reference.

"Explanation.

(1) Any dosage form of a medicine, other than the dosage form included in this Schedule, but in same strength and route of administration, which does not have significant difference in terms of pharmacokinetics or pharmacodynamics or efficacy- safety profile over the dosage form mentioned in the list shall be considered as included. To elaborate, if a tablet is included, other dosage forms like conventional tablets and capsules are considered as included. However, such different dosage forms should be considered differently for purposes such as procurement policy, pricing, etc. This principle also applies to all other dosage forms e.g. oral liquid dosage forms, injectables, topical dosage forms, etc.

It is pertinent to state that the cost of manufacturing the Subject Matter Formulation is different, the effect and the course of administration and treatment is different than the competitor's product. Thus, fixing of retail price of the formulation which has difference in cost of manufacturing, administration and efficacy cannot be equally applied.

presentation given by M/s Cipla Ltd. and observed that although the company claimed its product to be a superior product compared to the product of M/s Lupin available in market, but the company has not made suitable modifications in the product information leaflet so as to inform the patient and the licensing authorities about the same.

The committee further observed that M/s Cipla has failed to produce a separate license for its product and also did not apply to NPPA at any stage under para 11(3) for seeking separate price.

Moreover, the company also does not have published literature of their product, supporting the claims of improved efficacy over conventional products. The impact of the innovation on safety is also unknown, but simply extrapolated from the safety of the conventional product, from which the company claims significant modifications. The improved efficacy is also not apparent on the label of the product or through the license.

Further, the contention of the petitioner that cost of manufacturing is also different than the product of M/s Lupin is not tenable as the prices are fixed as per provisions of DPCO, 2013 and NPPP, 2012 which mandates price fixation relies on market-based data, and not cost based data.

gr

| | |
|---|--|
| <p>2. Additional price on account of Digital counter</p> <p>Further, the petitioner claimed that their product has an integrated dose counter, it is in fact pertinent to note that the Expert Committee, in the very same meeting, under Agenda no. 1 has recommended a separate price to Glenmark's "Budesonide+ Formoterol MDI Digital Inhalation under the brand "Digihaler" on the very same ground, viz. presence of digital dose counter.</p> <p>The relevant portion of 12th meeting held on July 31, 2019 is extracted hereunder: "Agenda No. 1 - Application of M/s Glenmark Pharmaceuticals Ltd for the separate price of "Budesonide+ Formoterol MDI Digital Inhalation under the brand "Digihaler" : The Committee observed that although the products have no additional therapeutic advantages, however, the presence of digital dose counter would help the patients in getting accurate measurement of dosage, low dose warning LED, end of dose display etc. Thus, the Committee is of the opinion that this is an incremental innovation and accordingly recommended that "Budesonide+ Formoterol MDI Digital Inhalation under the brand "Digihaler" may be separately priced.</p> | <p>This issue was also raised in the review petition filed to DoP, for which NPPA had given the reply.</p> <p>In this regard, it is stated that additional/ separate price for the "Budesonide + Formoterol MDI Digital Inhalation" was provided by the MDC in its 12th meeting as the applicant (M/S Glenmark) has applied for the same under Para 11(3) of DPCO, 2013.</p> <p>However, M/s Cipla Limited for their product "Beclomethasone + Formoterol" had not applied for additional / separate price in their application dated 07.02.2019. Also, M/s Cipla Limited had not claimed the same in their representation dated 17.05.2019, which was deliberated & rejected in 12th MDC.</p> <p>This issue of additional price on account of digital Dose counter was raised in the Writ Petition Filed in Hon'ble high court & review petition filed to DoP.</p> <p>Further, the matter was also deliberated in detail in 47th MDC meeting held on 02.12.2022, wherein representatives of M/s Cipla Limited requested for incremental price as their product is an innovation and claimed certain therapeutic advantages over the convention inhaler. Their product is an improved version, which will reach in small airways. The company also claimed that manufacturing process is highly complex compared to conventional formulation of the competitor. The same has been examined as per Point (1) above.</p> |
| <p>3. Documents Submitted by the Petitioner:</p> <p>i. The observation of the Committee</p> | <p>This issue was also raised in the review petition filed to DoP, for which NPPA had given the reply.</p> |

2

regarding the documents submitted by the Petitioner are completely unfounded. The entire set of documents, submitted by the Petitioner are being filed along with the present application.

- ii. It is further submitted that the extra-fine formulation of Beclomethasone and Formoterol developed by the Petitioner demonstrates adequate and comparable in- vitro deposition in the smaller airways as compared to the innovator developed product and marketed by Chelsi Pharmaceuticals, as shown by Anderson Cascade Impaction.

Hence the Petitioner's product can be expected to have a clinical efficacy comparable to that of the innovator.

Further, the matter was also deliberated in detail in 47th MDC meeting held on 02.12.2022, wherein the Committee noted the presentation given by M/s Cipla Ltd. and observed that although the company claimed its product to be a superior product compared to the product of M/s Lupin available in market, but the company has not made the patient and the licensing authorities aware about the same, such as through revisions in the product information leaflet.

The committee further observed that M/s Cipla has failed to produce the separate license for its product and also did not apply to NPPA at any stage under para 11(3) for seeking separate price.

Moreover, the company also does not have published literature of their product, supporting the claims of improved efficacy over conventional products. The impact of the innovation on safety is also unknown, but simply extrapolated from the safety of the conventional product, from which the company claims significant modifications. The improved efficacy is also not apparent on the label of the product or through the license.

4. Issue Regarding DCGI approval:

It is submitted that the approval or lack thereof cannot be one factors for the Expert Committee to recommend the retail price, the observation of the Committee that the product has no separate license from DCGI as required for a new drug, is completely baseless and far from the truth. It is submitted that no new drug license is required for the product as there is same composition is advanced owing to a smaller particle size.

This issue was also raised in the review petition filed to DoP, for which NPPA had given the reply.

Further, the matter was also deliberated in detail in 47th MDC meeting held on 02.12.2022, wherein the Committee noted the presentation given by M/s Cipla Ltd. and observed that although the company claimed its product to be a superior product compared to the product of M/s Lupin available in market, but the company

It is further submitted that the Subject Matter Formulation, for treatment of bronchial asthma, where use of inhaled corticosteroid therapy found appropriate has been approved by the DCGI on January 05, 2011

From the aforesaid it is amply evident that as there is significant difference in terms of pharmacokinetics, pharmacodynamics, and efficacy-safety profile in two dosage forms of a medicine therefore, for the purposes of pricing, they ought to have been treated as differently and their respective prices should have been determined Independently. Thus, the recommendation made by the Expert Committee, is not only without any scientific basis, but is also in contravention of the principles and provisions of DPCO 2013.

(M/s Cipla Limited) has not made the patient and the licensing authorities aware about the same, such as through revisions in the product information leaflet.

The committee further observed that M/s Cipla has failed to produce the separate license for its product and also did not apply to NPPA at any stage under para 11(3) for seeking separate price. The company also does not have published literature of their product, supporting the claims of improved efficacy over conventional products. The impact of the innovation on safety is also unknown, but simply extrapolated from the safety of the conventional product, from which the company claims significant modifications. The improved efficacy is also not apparent on the label of the product or through the license.

In this context, the member from DCGI office mentioned that if the product is a special/ separate product/ an innovative product, the company should apply for a separate license and get its product approved from competent authority/regulator.

7. In view of the above, the Committee did not find any merit and recommended that the matter may be treated as closed.

Agenda Item No. 3: Application by M/s Cadila Pharmaceuticals Limited for exemption from the provisions of Drug Price Control Order 2013 under Para 32 (i) & (ii) for their product Cholecalciferol Aqueous Injection 6,00,000 IU/2ml (Vitamin D3 Injection)" – reg.

1. The matter relates to exemption under Para 32 (i) & (ii) for the formulations "Cholecalciferol Aqueous Injection 6,00,000 IU/2ml (Vitamin D3 Injection)" applied by M/s Cadila Pharmaceuticals Limited vide e-mail dated 08.05.2023 and 06.07.2023. The applicant vide letter dated 08.05.2023 submitted the application for exemption under Para 32 along with copy of Patent issued by the Patent Office under Indian Patent Act, 1970 dated 04.05.2023 for "AN AQUEOUS PARENTERAL COMPOSITION OF VITAMIN D3" bearing registration no. 431119 and the claim filed with Patent Office (Application No. 201821004137) dated 03.02.2018.

R

3. The Committee observed that:

- a. Cholecalciferol is listed in section 26.4 of Schedule-I of DPCO, 2013 as "Solid oral dosage form 1000 IU, Solid oral dosage form 60000 IU and Oral liquid 400 IU/ML". The applicant has applied for exemption of Cholecalciferol Aqueous Injection 6,00,000 IU/2ml (Vitamin D3 Injection)".
- b. NPPA has earlier not fixed the retail price fixation of for the drug 'Cholecalciferol Aqueous Injection 600000 IU / 2ml (Vitamin D3 Injection)'. One application received for retail price fixation of 'Cholecalciferol injection 600000 IU/ 1 ML' was rejected due to non-submission of DCGI approval.
- c. Applicant has submitted the Patent Certificate No. 431119 dated 04.05.2023 valid for the term of 20 years from the 03.02.2018 for "AN AQUEOUS PARENTERAL COMPOSITION OF VITAMIN D3".
- d. As per Patent certificate, patent is granted for an invention entitled "AN AQUEOUS PARENTERAL COMPOSITION OF VITAMIN D3".
- e. Applicant has submitted CDSCO permission No. MF/SND/23/000059 dated 17.04.2023 for "Cholecalciferol Aqueous Injection 6,00,000 IU/2ml".
- f. State Licensing permission no. G/28/1090 dated 24.04.2023 for "Cholecalciferol Aqueous Injection 6,00,000 IU/2ml".
- g. Applicant has submitted a declaration that it does not have proposal to discontinue or reduce production of the scheduled formulation.
- h. Applicant has submitted production and sales data of Scheduled formulation for last 6 quarters duly certified by CA/CMA and submitted a declaration that the applied formulation is not prohibited by DCGI/MoH&FW.
- i. Applicant has also submitted clinical study report of the applied formulation.

4. The committee observed that letters dated 20.7.2023 and 07.08.2023 were sent to Patent Office seeking confirmation as to whether the formulation for which exemption is sought is covered under the scope of Patent granted to M/s Cadila Pharmaceuticals Limited as mentioned in Point 1 above. Patent office vide their email dated 15.08.2023 stated as follows:

"Analysis of the granted Patent No. 431119:

"A stable aqueous parenteral composition comprising 300000 to 600000 IU/ml of Vitamin D3 along with other excipients as well as a process for preparation of the same has been granted a patent (Patent No. 431119). The title of the specification is AN AQUEOUS PARENTERAL COMPOSITION OF VITAMIN D3.

As sought to provide confirmation as per the letter dated 20.07.2023 of NPPA, the formulation i.e., Cholecalciferol aqueous injection 6,00,000 IU/2ml (Vitamin D3 injection) and the process through which it is developed are covered under the scope of Patent granted for "AN AQUEOUS PARENTERAL COMPOSITION OF VITAMIN D3" to M/s Cadila Pharmaceuticals Limited, it is informed that the same is within the scope of the patent granted.

Vitamin D3 is otherwise known as cholecalciferol and the composition comprising the same as granted is 300000 to 600000 IU/ml of Vitamin D3 or 600000 IU/2ml if the lower side range is considered."

92

5. The Committee also noted the submission of the applicant with respect to the need, benefits, and superiority of an Aqueous Parenteral composition of Vitamin D3 claimed as follows:

- a) Cholecalciferol Aqueous Injection 600000 IU / 2ml (Vitamin D3 Injection) of Cadila Pharmaceuticals Ltd is world's first water- based Injection.
- b) The Company strongly believes that only the new water-based injection demonstrates significantly enhanced "efficacy" over the oil-based injections.
- c) Compared to conventional formulation, the aqueous formulation rapidly increases the level of serum 25(OH)D (within one hour).
- d) Oil containing injectable formulation can cause pain, erythema, swelling nodule formation at the site of injection. They have to be injected deep intramuscularly.

6. The Committee deliberated upon the matter in detail and based on the inputs of the Patent officer recommended that exemption may be granted to M/s Cadila Pharmaceuticals Limited under Para 32(i) and 32(ii) of DPCO, 2013 with respect to the formulation "Cholecalciferol Aqueous Injection 6,00,000 IU/2ml (Vitamin D3 Injection)" as the same is covered under the scope of patent granted by the Patent Office.

Agenda Item No. 4: Application filed by M/s Panacea Biotech Limited for exemption under para 32 (i) to (iii) of DPCO, 2013 for their product EasyfourPol (DTwP-Hib-IPV) Vaccine-reg.

1. The committee noted that M/s Panacea Biotech Limited vide e-mail dated 06.03.2023 applied for the exemption under Para 32 for the formulations EasyfourPol Vaccine containing "Adsorbed Diphtheria, Tetanus, Pertussis, Poliomyelitis (Inactivated) and Haemophilus Influenzae Type b Conjugate Vaccine IP" & further requested on 29.06.2023 that exemption may be granted under Para 32(i). The applicant vide letter dated 06.03.2023 submitted the application for exemption along with the copy of Patent issued by the Patent Office under Indian Patent Act, 1970 dated 30.03.2016 for "Novel Combination Vaccines with Whole Cell Pertussis and method of manufacturing the same" bearing registration no. 272351 and the claim filed with Patent Office (Application No. 2437/DEL/2008) dated 24.10.2008.

2. The Committee further observed that:

- a. MoH&FW vide their letter dated 11.11.2022 confirmed that the vaccine i.e. EasyfourPol (DTwP-Hib-IPV) Vaccine for which applicant has applied for exemption under Para 32 is not covered under Universal Immunization Program (UIP).
- b. Applicant has submitted the copy of Patent issued by the Patent Office under Indian Patent Act, 1970 dated 30.03.2016 for "Novel Combination Vaccines with Whole Cell Pertussis and method of manufacturing the same" bearing registration no. 272351 along with the claim filed with Patent Office (Application No. 2437/DEL/2008) dated 24.10.2008.
- c. Applicant has submitted the DCGI permission bearing registration no. BIO/MA/21/000121 dated 01.05.2022 & State Licensing Authority Permission No. MB/07/632 dated 14.11.2022 valid upto 28.09.2027.

A

3. The committee noticed that letters dated 18.04.2023 and 26.04.2023 were sent to Patent Office seeking confirmation as to whether the formulation for which exemption is sought is covered under the Patent granted to M/s Panacea biotech Limited. Further, complete application as received from the applicant was also sent to Patent Office on 30.5.2023 seeking their comments. Patent office vide their email dated 23.06.2023 stated as follows:

".....and to inform you that the product for which the exemption is applied, i.e. EasyfourPol Vaccine, containing "Adsorbed Diphtheria, Tetanus, Pertussis, Poliomyelitis (Inactivated) and Haemophilus Influenzae Type b Conjugate Vaccine IP" is covered under the scope of Patent No. 272351 granted for "Novel Combination Vaccines with Whole Cell Pertussis and method of manufacturing the same" to M/s Panacea Biotech Limited."

4. The committee also noted that while providing the above inputs, the Patent Office has referred to the NPPA's letter dated 26.04.2023 wherein copy of patent certificate and claim copy were enclosed. As such, Patent Office was requested vide mail dated 28.06.2023, 10.07.2023 and 27.07.2023 to confirm whether the observations of the Patent Office as sent on 23.06.2023 hold good in view of the complete application shared by NPPA on 30.05.2023. However, Patent Office has not submitted any contrary view on the same.

5. The Committee deliberated upon the matter and the inputs of the Patent office in detail and observed that M/s Panacea Biotech Limited fulfills the conditions of Para 32(i) of DPCO, 2013 with respect to the formulation EasyfourPol Vaccine containing "Adsorbed Diphtheria, Tetanus, Pertussis, Poliomyelitis (Inactivated) and Haemophilus Influenzae Type b Conjugate Vaccine IP". Accordingly, the Committee recommended that exemption may be granted to M/s Panacea Biotech Limited under Para 32(i) of DPCO, 2013 with respect to the formulation EasyfourPol Vaccine containing "Adsorbed Diphtheria, Tetanus, Pertussis, Poliomyelitis (Inactivated) and Haemophilus Influenzae Type b Conjugate Vaccine IP".

Agenda Item No. 5(i): Retail price fixation under Para 5 of DPCO, 2013 – Each film coated bilayered tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100 mg + Pioglitazone Hydrochloride IP eq. to Pioglitazone 15 mg + Metformin Hydrochloride IP 1000 mg (as sustained release Form) for M/s Akums Drugs & Pharmaceuticals Ltd (manufacturer) and M/s Zuventus Healthcare Ltd (marketer) (F.No. 3560) at Rs. 17.16 per tablet excluding GST.

1. The committee, deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

| | | |
|---|-----------------------------|---|
| 1 | Manufacturer Name | M/s Akums Drugs & Pharmaceuticals Ltd |
| 2 | Marketer Name | M/s Zuventus Healthcare Ltd (Applicant) |
| 3 | Date of Application | 03.08.2023 |
| 4 | Patented Component I | Sitagliptin |
| 5 | Patent Holder | M/S MSD Pharmaceuticals Private Ltd. |

2

| | | |
|---|-----------------------|----------------|
| 6 | License Holder | M/s Sun Pharma |
| 7 | Date of Patent Expiry | 05.07.2022 |

Calculation of Retail Price (Rupees)

| S.N. | Particulars | Data Month | Option-I Sitagliptin (100mg) + Metformin (1000mg) | Option-II Pioglitazone(15mg) + Metformin (1000mg) |
|------|--|------------|---|--|
| A. | Retail price of FDC excluding Patent & License Holder | Jan 23 | 13.51 | 9.70 |
| B. | Other Component excluding Patent & License Holder | Jan 23 | 4.56 (Pioglitazone 15mg) | 10.86 (Sitagliptin 100mg) |
| C. | Total | | 18.07 | 20.56 |
| D. | Less: 20% of lower of A&B | | 0.91 | 1.94 |
| E. | Calculated Price of applied FDC | | 17.16 | 18.62 |
| F. | Claimed Price | | 29.00 | 29.00 |
| G. | Recommended Price (Lower of worked out and claimed price) per tablet | | | 17.16 |

Agenda Item No. 5(ii): Retail price fixation under Para 5 of DPCO, 2013 – Each film coated bilayered tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100 mg + Pioglitazone Hydrochloride IP eq. to Pioglitazone 15 mg + Metformin Hydrochloride IP 500 mg (as sustained release Form) for M/s Akums Drugs & Pharmaceuticals Ltd (manufacturer) and M/s Zuventus Healthcare Ltd (marketer) (F.No. 3559)at Rs. 16.09 per tablet excluding GST.

1. The committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

| | | |
|---|-----------------------|--|
| 1 | Manufacturer Name | M/s Akums Drugs & Pharmaceuticals Ltd |
| 2 | Marketer Name | M/s Zuventus Healthcare Ltd(Applicant) |
| 3 | Date of Application | 03.08.2023 |
| 4 | Patented Component I | Sitagliptin |
| 5 | Patent Holder | M/S MSD Pharmaceuticals Private Ltd. |
| 6 | License Holder | M/s Sun Pharma |
| 7 | Date of Patent Expiry | 05.07.2022 |

Calculation of Retail Price (Rupees)

| S.N. | Particulars | Data Month | Option - I Sitagliptin (100mg) + Metformin (500mg) | Option - II Pioglitazone(15mg) + Metformin (500mg) |
|------|-------------------------------|------------|--|---|
| A. | Retail price of FDC excluding | Jan 23 | 12.44 | 7.80 |

A/V

| | | | | |
|----|--|--------|-----------------------------|------------------------------|
| | Patent & License Holder | | | |
| B. | Other Component excluding Patent & License Holder | Jan 23 | 4.56 (Pioglitazone 15mg) | 10.86 (Sitagliptin 100mg) |
| C. | Total | | 17.00 | 18.66 |
| D. | Less: 20% of lower of A&B | | 0.91 | 1.56 |
| E. | Calculated Price of applied FDC | | 16.09 | 17.10 |
| F. | Claimed Price | | 27.00 | 27.00 |
| G. | Recommended Price (Lower of worked out and claimed price) per tablet | | | 16.09 |

Agenda Item No. 5(iii): Retail price fixation under Para 5 of DPCO, 2013 – Each film coated bilayered tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100 mg + Pioglitazone Hydrochloride IP eq. to Pioglitazone 15 mg + Metformin Hydrochloride IP 1000 mg (as sustained release Form) for M/s Akums Drugs & Pharmaceuticals Ltd (manufacturer) and M/s Primus Remedies Pvt Ltd (marketer) (F. No. 3565) at Rs. 17.16 per tablet excluding GST.

1. The committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

| | | |
|---|-----------------------|---|
| 1 | Manufacturer Name | M/s Akums Drugs & Pharmaceuticals Ltd |
| 2 | Marketer Name | M/s Primus Remedies Pvt Ltd (Applicant) |
| 3 | Date of Application | 03.08.2023 |
| 4 | Patented Component I | Sitagliptin |
| 5 | Patent Holder | M/S MSD Pharmaceuticals Private Ltd. |
| 6 | License Holder | M/s Sun Pharma |
| 7 | Date of Patent Expiry | 05.07.2022 |

Calculation of Retail Price (Rupees)

| S.N. | Particulars | Data Month | Option-I Sitagliptin (100mg) + Metformin (1000mg) | Option-II Pioglitazone(15mg) + Metformin (1000mg) |
|------|--|------------|---|--|
| A. | Retail price of FDC excluding Patent & License Holder | Jan 23 | 13.51 | 9.70 |
| B. | Other Component excluding Patent & License Holder | Jan 23 | 4.56 (Pioglitazone 15mg) | 10.86 (Sitagliptin 100mg) |
| C. | Total | | 18.07 | 20.56 |
| D. | Less: 20% of lower of A&B | | 0.91 | 1.94 |
| E. | Calculated Price of applied FDC | | 17.16 | 18.62 |
| F. | Claimed Price | | 17.69 | 17.69 |
| G. | Recommended Price (Lower of worked out and claimed price) per tablet | | | 17.16 |

92

Agenda Item No. 5(iv): Retail price fixation under Para 5 of DPCO, 2013 – Each film coated bilayered tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100 mg + Pioglitazone Hydrochloride IP eq. to Pioglitazone 15 mg + Metformin Hydrochloride IP 500 mg (as sustained release Form) for M/s Akums Drugs & Pharmaceuticals Ltd (manufacturer) and M/s Primus Remedies Pvt Ltd (marketer) (F. No. 3566)at Rs. 16.09 per tablet excluding GST.

1. The committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

| | | |
|---|-----------------------|---|
| 1 | Manufacturer Name | M/s Akums Drugs & Pharmaceuticals Ltd |
| 2 | Marketer Name | M/s Primus Remedies Pvt Ltd.(Applicant) |
| 3 | Date of Application | 03.08.2023 |
| 4 | Patented Component I | Sitagliptin |
| 5 | Patent Holder | M/S MSD Pharmaceuticals Private Ltd. |
| 6 | License Holder | M/s Sun Pharma |
| 7 | Date of Patent Expiry | 05.07.2022 |

Calculation of Retail Price (Rupees)

| S.N. | Particulars | Data Month | Option-I Sitagliptin (100mg) + Metformin (500mg) | Option-II Pioglitazone(15mg) + Metformin (500mg) |
|------|---|------------|--|---|
| A. | Retail price of FDC excluding Patent & License Holder | Jan 23 | 12.44 | 7.80 |
| B. | Other Component excluding Patent & License Holder | Jan 23 | 4.56 (Pioglitazone 15mg) | 10.86 (Sitagliptin 100mg) |
| C. | Total | | 17.00 | 18.66 |
| D. | Less: 20% of lower of A&B | | 0.91 | 1.56 |
| E. | Calculated Price of applied FDC | | 16.09 | 17.10 |
| F. | Claimed Price | | 16.33 | 16.33 |
| G. | Recommended Price (Lower of worked out and claimed price) per tablet | | | 16.09 |

Agenda Item No. 6 (i): Retail price fixation under Para 5 of DPCO, 2013-Each film coated bilayer tablet contains: Linagliptin IP 5mg + Metformin Hydrochloride (as extended release) IP 1000mg for M/s Exemed Pharmaceuticals (Manufacturer) & M/s Eris Lifesciences Ltd. (Marketer) (F. No. 3577)at Rs. 14.37 per tablet excluding GST.

1. The committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

Pr

| | | |
|----------|--|---|
| 1 | Manufacturer Name | M/s Exemed Pharmaceuticals |
| 2 | Marketer Name | M/s Eris Lifesciences Ltd. (Applicant) |
| 3 | Date of Application | 11.08.2023 |
| 4 | Patented Component | Linagliptin |
| 5 | Patent Holder | M/s Boehringer Ingelheim |
| 6 | License Holder | M/s Lupin Limited |
| 7 | Date of Patent Expiry | 21.02.2022 |
| 8 | Calculation of Retail price | |
| | Calculated Price | |
| A | Price as on 6 months prior to application date excluding price of Patent/ license holder (Jan, 2023) | 11.48 |
| B | Metformin Modified Release 1000 mg (Ceiling Price [SO. 89(E) dated 06.01.2023]) | 3.61 |
| C | Total | 15.09 |
| D | Less: 20% of the lower of (A) and (B) | 0.72 |
| E | Worked out Retail Price (C-D) | 14.37 |
| F | Claimed Retail price | 35.71 |
| G | Recommended Price (Lower of worked out and claimed price) per tablet | 14.37 |

Agenda Item No. 6 (ii): Retail price fixation under Para 5 of DPCO, 2013-Each film coated bilayered tablet contains: Linagliptin 5mg + Metformin Hydrochloride IP 1000mg (Extended-release form) for M/s AlkemHealthscience (A unit of Alkem Laboratory Ltd.) (Manufacturer) & M/s Alkem Laboratories Ltd. (Marketer) (F. No.3585) at Rs. 14.37 per tablet excluding GST.

1. The committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

| | | |
|---|------------------------------------|--|
| 1 | Manufacturer Name | M/s AlkemHealthscience (A unit of Alkem Laboratory Ltd.) |
| 2 | Marketer Name | M/s Alkem Laboratories Ltd. (Applicant) |
| 3 | Date of Application | 16.08.2023 |
| 4 | Patented Component | Linagliptin |
| 5 | Patent Holder | M/s Boehringer Ingelheim |
| 6 | License Holder | M/s Lupin Limited |
| 7 | Date of Patent Expiry | 21.02.2022 |
| 8 | Calculation of Retail price | |

h

| | | |
|---|---|--------------|
| | Calculated Price | |
| A | Price as on 6 months prior to application date excluding price of Patent/ license holder (Jan,2023) | 11.48 |
| B | Metformin Modified release 1000 mg (Ceiling Price [SO. 89(E) dated 06.01.2023]) | 3.61 |
| C | Total | 15.09 |
| D | Less: 20% of the lower of (A) and (B) | 0.72 |
| E | Worked out Retail Price (C-D) | 14.37 |
| F | Claimed Retail price | 26.34 |
| G | Recommended Price (Lower of worked out and claimed price) per tablet | 14.37 |

Agenda Item No. 6 (iii): Retail price fixation under Para 5 of DPCO, 2013-Each film coated bilayered tablet contains: Linagliptin 5mg + Metformin Hydrochloride IP 500mg (Extended-release form) for M/s Alkem Healthscience (A unit of Alkem Laboratory Ltd.) (Manufacturer) & M/s Alkem Laboratories Ltd. (Marketer) (F. No.3584) at Rs. 12.92 per tablet excluding GST.

1. The committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

| | | |
|---|---|---|
| 1 | Manufacturer Name | M/s Alkem Healthscience (A unit of Alkem Laboratory Ltd.) |
| 2 | Marketer Name | M/s Alkem Laboratories Ltd. (Applicant) |
| 3 | Date of Application | 16.08.2023 |
| 4 | Patented Component | Linagliptin |
| 5 | Patent Holder | M/s Boehringer Ingelheim |
| 6 | License Holder | M/s Lupin LTD |
| 7 | Date of Patent Expiry | 21.02.2022 |
| 8 | Calculation of Retail price | |
| | Calculated Price | |
| A | Price as on 6 months prior to application date excluding price of Patent/ license holder (Jan,2023) | 11.48 |
| B | Metformin 500 mg (Ceiling Price [SO. 89(E) dated 06.01.2023]) | 1.80 |
| C | Total | 13.28 |
| D | Less: 20% of the lower of (A) and (B) | 0.36 |
| E | Worked out Retail Price (C-D) | 12.92 |
| F | Claimed Retail price | 19.20 |
| G | Recommended Price (Lower of worked out and claimed price) per tablet | 12.92 |

Agenda Item No. 7 (i): Retail price fixation of Each ml contains: Insulin glargine IP 100U (3.6378mg)&Lixisenatide 0.05mg for M/s Sanofi Healthcare India Pvt. Ltd. (Manufacturer) and M/s Sanofi India Limited (Marketer) under DPCO, 2013 (F.No. 3457) at Rs. 587.30 per ml excluding GST.

1.The committee noted that Insulin glargine 100 IU is a schedule formulation & its present applicable ceiling price is Rs. 181.45 / ml. The committee also noted that Lixisenatide is a non-schedule formulation and is a product of M/s Sanofi India Ltd. and has limited sales as reported in Pharmatrac in last 3 year. The details are as follows:

| Formulation & Year | Units Sold | Value (Rs. In Lacs) |
|---------------------------|------------|---------------------|
| Lixisenatide 10MCG | | |
| Sep 20 – Aug 21 | 7 | 0.22 |
| Sep 21 – Aug 22 | 6 | 0.19 |
| Sep 22 – Aug 23 | 0 | 0.00 |
| Lixisenatide 20MCG | | |
| Sep 20 – Aug 21 | 620 | 19.43 |
| Sep 21 – Aug 22 | 210 | 6.58 |
| Sep 22 – Aug 23 | 0 | 0 |

2. The Committee deliberated upon the matter & directed that M/s Sanofi India Ltd. may be called in the next MDC meeting to present their case w.r.t. to market dynamics of Lixisenatide, therapeutic advantage of FDC of Lixisenatide + Insulin Glargine over schedule formulation Insulin Glargine.

Agenda Item No. 7 (ii): Retail price fixation of each ml contains: Insulin glargine IP 100U (3.6378mg) & Lixisenatide 0.033mg for M/s Sanofi Healthcare India Pvt. Ltd. (Manufacturer) and M/s Sanofi India Limited (Marketer) under DPCO, 2013 (F. No. 3458) at Rs. 587.30 per ml excluding GST.

1. The committee noted that Insulin glargine 100 IU is a schedule formulation & its present applicable ceiling price is Rs. 181.45 / ml. The committee also noted that Lixisenatide is a non-schedule formulation and is a product of M/s Sanofi Group, has limited sales as reported in Pharmatrac in last 3 year. The details are as follows:

| Formulation & Year | Units Sold | Value (In Lacs) |
|---------------------------|------------|-----------------|
| Lixisenatide 10MCG | | |
| Sep 20 – Aug 21 | 7 | 0.22 |
| Sep 21 – Aug 22 | 6 | 0.19 |
| Sep 22 – Aug 23 | 0 | 0.00 |
| Lixisenatide 20MCG | | |
| Sep 20 – Aug 21 | 620 | 19.43 |
| Sep 21 – Aug 22 | 210 | 6.58 |
| Sep 22 – Aug 23 | 0 | 0 |

Handwritten signature

2. The Committee deliberated upon the matter & directed that M/s Sanofi India Ltd. may be called in the next MDC meeting to present their case w.r.t. to market dynamics of Lixisenatide, therapeutic advantage of FDC of Lixisenatide + Insulin Glargine over schedule formulation Insulin Glargine.

Agenda Item No. 8: Application for “Special Feature rate” for schedule Product under para 11(3).

1. The committee noted that the M/s Gufic Biosciences Limited vide letter dated 19.07.2023 applied for 'Special Feature rate' of scheduled product under para 11(3) as the formulation will be manufactured under 'New Drug Delivery System' namely packing in DCB(Dual Chamber Bags) as detailed below:

| Sl. No. | Product Name | Composition | Proposed Ceiling Price | Existing Ceiling Price | Proposed % increase |
|---------|------------------------|--------------------------|------------------------|------------------------|---------------------|
| 1 | Merofic DCB 500 MG INJ | Meropenem Sterile 500 MG | Rs. 1000 | Rs.722.97 | 38.32 % |
| 2 | Merofic DCB 1 GM INJ | Meropenem Sterile 1 GM | Rs.1300 | Rs.952.68 | 36.46 % |

2. The committee also observed that the Meropenem is scheduled formulation and present applicable ceiling price are as below:

| Sl No | Medicines | Dosage form and strength | Unit | Ceiling price (w.e.f 01.04.2023 after WPI revision @ 12.1218%) |
|-------|-----------|--|--------|--|
| 1. | Meropenem | Powder for Injection 500mg (as trihydrate) | 1 Vial | 722.98 |
| 2. | Meropenem | Powder for Injection 1 Gm (as trihydrate) | 1 Vial | 952.68 |

3. The committee deliberated upon the special features claimed by the applicant for dual chamber bags and decided that the applicant may be called in the next meeting of MDC to demonstrate their product & explain the special features.

Agenda Item No. 9(i): Retail price fixation under Para 5 of DPCO, 2013 – Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50 mg + Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 5 mg + Metformin Hydrochloride IP 1000 mg for M/s Exemed Pharmaceuticals (manufacturer) and M/s Eris Lifesciences Ltd (marketer) (F. No. 3562) at Rs. 14.62 per tablet excluding GST.

1. The committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

| | | |
|---|--------------------------|---------------------------------------|
| 1 | Manufacturer Name | M/s Exemed Pharmaceuticals |
| 2 | Marketer Name | M/s Eris Lifesciences Ltd.(Applicant) |

Ar

| | | |
|----|-----------------------|--|
| 3 | Date of Application | 03.08.2023 |
| 4 | Patented Component I | Sitagliptin |
| 5 | Patent Holder | M/s MSD Pharmaceuticals Private Ltd. |
| 6 | License Holder | M/s Sun Pharma |
| 7 | Date of Patent Expiry | 05.07.2022 |
| 8 | Patented Component II | Dapagliflozin |
| 9 | Patent Holder | M/s Astra Zeneca |
| 10 | License Holder | M/s Sun Pharma & M/s Abbott Healthcare |
| 11 | Date of Patent Expiry | 02.10.2020 |

Calculation of Retail Price

| S.N. | Particulars | Data Month | Option I Sitagliptin (50mg) + Metformin (1000mg) | Option II Dapagliflozin(5mg) + Metformin (1000mg) |
|------|---|------------|---|--|
| A. | Retail price of FDC excluding Patent & License Holder | Jan 23 | 10.37 | 8.24 |
| B. | Other Component excluding Patent & License Holder | Jan 23 | 8.86 (Dapagliflozin 5mg) | 7.97 (Sitagliptin 50mg) |
| C. | Total | | 19.23 | 16.21 |
| D. | Less: 20% of lower of A&B | | 1.77 | 1.59 |
| E. | Calculated Price of applied FDC | | 17.46 | 14.62 |
| F. | Claimed Price | | 35.71 | 35.71 |
| G. | Recommended Price (Lower of worked out and claimed price) per tablet | | | 14.62 |

Agenda Item No. 9 (ii): Retail price fixation under Para 5 of DPCO, 2013 – Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50 mg + Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 5 mg + Metformin Hydrochloride IP 500 mg for M/s Exemed Pharmaceuticals (manufacturer) and M/s Eris Lifesciences Ltd (marketer) (F. No. 3561) at Rs. 13.55 per tablet excluding GST.

1. The committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:


| | | |
|---|--------------------------|----------------------------|
| 1 | Manufacturer Name | M/s Exemed Pharmaceuticals |
|---|--------------------------|----------------------------|

| | | |
|----|------------------------------|--|
| 2 | Marketer Name | M/s Eris Lifesciences Ltd. (Applicant) |
| 3 | Date of Application | 03.08.2023 |
| 4 | Patented Component I | Sitagliptin |
| 5 | Patent Holder | M/s MSD Pharmaceuticals Private Ltd. |
| 6 | License Holder | M/s Sun Pharma |
| 7 | Date of Patent Expiry | 05.07.2022 |
| 8 | Patented Component II | Dapagliflozin |
| 9 | Patent Holder | M/s Astra Zeneca |
| 10 | License Holder | M/s Sun Pharma & M/s Abbott Healthcare |
| 11 | Date of Patent Expiry | 02.10.2020 |

Calculation of Retail Price

| S.N. | Particulars | Data Month | Option I | Option II |
|-----------|---|------------|--|--|
| | | | Sitagliptin (50mg) + Metformin (500mg) | Dapagliflozin(5mg) + Metformin (500mg) |
| A. | Retail price of FDC excluding Patent & License Holder | Jan 23 | 9.16 | 6.98 |
| B. | Other Component excluding Patent & License Holder | Jan 23 | 8.86 (Dapagliflozin 5mg) | 7.97 (Sitagliptin 50mg) |
| C. | Total | | 18.02 | 14.95 |
| D. | Less: 20% of lower of A&B | | 1.77 | 1.40 |
| E. | Calculated Price of applied FDC | | 16.25 | 13.55 |
| F. | Claimed Price | | 26.78 | 26.78 |
| G. | Recommended Price (Lower of worked out and claimed price) per tablet | | | 13.55 |

The meeting ended with a vote of thanks to all.


 (Rashmi Tahiliani)
 Joint Director (Pricing)

Copy to:
All members of the Committee.

Computation of Retail Price based on January, 2023 Data under Para 5 of DPCO, 2013

Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100 mg + Metformin Hydrochloride IP 1000 mg (as sustained release Form)

| | | | | | |
|--|--|--|--|--|--------|
| Number of Companies consisting of Market Share of 1% & Above | | | | | 12 |
| Sum of MAT value considered for price calculation (In Lakhs) | | | | | 844.65 |
| Sum of PTR per unit considered for price calculation | | | | | 221.39 |
| Number of Packs considered | | | | | 19 |
| Average PTR | | | | | 11.65 |
| Add : 16% Retailer Margin | | | | | 1.86 |
| Retail Price (without local taxes) | | | | | 13.51 |
| % Reduction with compared to Highest Price | | | | | 18.02% |

| | | | |
|---------------------------------|--|--|-------|
| Minimum Price (Rs.) | | | 9.93 |
| Maximum Price (Rs.) | | | 14.21 |
| Average of all considered (Rs.) | | | 11.65 |
| Retail Price (Rs.) | | | 13.51 |

| S.No. | पैक विवरण Pack Description | उत्प BRAND | कंपनी Company | Strength | Pack Size | Unit | TOTAL MAT | 8,82,80,114 | 100% | Brandwise e MAT (ignoring 0% MAT) | Quality (Y/N) Y=Yes N=No | M3 Price per Unit (Rs.) | Price per Unit (Rs.) Considered |
|-------|---|---------------|----------------------------------|-------------|-----------|-----------|-----------|-------------|-------------------|--|--------------------------------|----------------------------------|---------------------------------------|
| | | | | | | | PTR(Rs.) | MAT(Rs.) | SKU wise MAT % | | | | |
| 1 | SIAGLUDE M OD 100/1000 MG TABLET 15 | SIAGLUDE M | ABBOTT HEALTHCARE PVT. LTD | 100/1000 MG | 15 | TABLET | 212.25 | 8003947.50 | 9.07% | 9.07% | Y | 14.15 | 14.15 |
| 2 | ACSITA M 100/1000 MG TABLET SR 10 | ACSITA M | ACMEDIX PHARMA LLP | 100/1000 MG | 10 | TABLET SR | 63.57 | 40049.10 | 0.05% | 0.05% | N | 6.36 | |
| 3 | SITAMAX M 100/1000 MG TABLET 10 | SITAMAX M | AJANTA PHARMA LTD | 100/1000 MG | 10 | TABLET | 106.43 | 94722.70 | 0.11% | 0.11% | N | 10.64 | |
| 4 | SITALEMBIC M 100/1000 MG TABLET SR 15 | SITALEMBIC M | ALEMBIC LTD | 100/1000 MG | 15 | TABLET SR | 150 | 546150.00 | 0.62% | 0.62% | N | 10.00 | |
| 5 | ALSITA M FORTE 100/1000 MG TABLET 10 | ALSITA M | ALKEM LABORATORIES LTD. | 100/1000 MG | 10 | TABLET | 99.29 | 5820379.80 | 6.59% | 6.59% | Y | 9.93 | 9.93 |
| 6 | SIDIAMET FORTE 100/1000 MG TABLET XR 15 | SIDIAMET | APRICA HEALTHCARE PVT LTD | 100/1000 MG | 15 | TABLET XR | 171.43 | 284916.66 | 0.32% | 0.32% | N | 11.43 | |
| 7 | SITAGLO MSR FORTE 100/1000 MG TABLET 10 | SITAGLO MSR | ARISTO PHARMACEUTICALS PVT.LTD | 100/1000 MG | 15 | TABLET | 148.93 | 184971.06 | 0.21% | 0.21% | N | 9.93 | |
| 8 | SITACIP M 100/1000 MG TABLET 10 | SITACIP M | CIPLA LTD. | 100/1000 MG | 10 | TABLET | 113.57 | 3508419.81 | 3.97% | 3.97% | Y | 11.36 | 11.36 |
| 9 | SITABITE M 100/1000 MG TABLET SR 10 | SITABITE M | CORONA | 100/1000 MG | 10 | TABLET SR | 113.57 | 574323.49 | 0.65% | 0.65% | N | 11.36 | |
| 10 | EMSITA M 100/1000 MG TABLET SR 10 | EMSITA M | EMCURE PHARMACEUTICALS LTD | 100/1000 MG | 10 | TABLET SR | 135.64 | 3902362.80 | 4.42% | 4.42% | Y | 13.56 | 13.56 |
| 11 | GLURA M FORTE 100/1000 MG TABLET XR 15 | GLURA M | ERIS LIFESCIENCES LTD | 100/1000 MG | 15 | TABLET XR | 171.43 | 6393996.14 | 7.24% | 7.24% | Y | 11.43 | 11.43 |
| 12 | CTASORIN M FORTE 100/1000 MG TABLET 10 | CTASORIN M | FUSION HEALTHCARE PVT LTD | 100/1000 MG | 10 | TABLET | 135.71 | 538497.28 | 0.61% | 0.61% | N | 13.57 | |
| 13 | SITAZIT M 100/1000 MG TABLET ER 10 | SITAZIT M | GLENMARK PHARMACEUTICALS LTD. | 100/1000 MG | 10 | TABLET ER | 142.14 | 4877960.52 | 5.53% | 5.53% | Y | 14.21 | 14.21 |
| 14 | QSITA M 100/1000 MG TABLET SR 10 | QSITA M | HBC LIFESCIENCES PVT LTD | 100/1000 MG | 10 | TABLET SR | 85.71 | 657481.41 | 0.74% | 0.74% | N | 8.57 | |
| 15 | IGNAUS M 100/1000 MG TABLET 10 | IGNAUS M | INTAS PHARMACEUTICALS LTD | 100/1000 MG | 10 | TABLET | 106.43 | 6562048.08 | 7.43% | 7.43% | Y | 10.64 | 10.64 |
| 16 | SITARA-M 100/1000 MG TABLET 10 | SITARA-M | INTAS PHARMACEUTICALS LTD | 100/1000 MG | 10 | TABLET | 106.43 | 6380584.93 | 7.23% | 7.23% | Y | 10.64 | 10.64 |
| 17 | SUITGLIP M 100/1000 MG TABLET XR 10 | SUITGLIP M | IPCA LABORATORIES PVT LTD. | 100/1000 MG | 10 | TABLET XR | 103.57 | 151315.77 | 0.17% | 0.17% | N | 10.36 | |
| 18 | SITAHENZ M OD 100/1000 MG TABLET 10 | SITAHENZ M OD | LA RENON | 100/1000 MG | 10 | TABLET | 141.43 | 5663847.21 | 6.42% | 6.42% | Y | 14.14 | 14.14 |
| 19 | SUGARAY M 100/1000 MG TABLET SR 15 | SUGARAY M | LLOYD HEALTHCARE PVT.LTD | 100/1000 MG | 15 | TABLET SR | 170.37 | 420813.90 | 0.48% | 0.48% | N | 11.96 | |
| 20 | LUPISIT M 100/1000 MG TABLET XR 10 | LUPISIT M | LUPIN LTD | 100/1000 MG | 10 | TABLET XR | 103.57 | 91970.16 | 0.10% | 0.10% | N | 10.36 | |
| 21 | MACSITA M 100/1000 MG TABLET 10 | MACSITA M | MACLEODS PHARMACEUTICALS PVT.LTD | 100/1000 MG | 10 | TABLET | 102.86 | 98539.88 | 0.11% | 2.16% | Y | 10.29 | 10.29 |
| 22 | MACSITA M 100/1000 MG TABLET XR 10 | MACSITA M | MACLEODS PHARMACEUTICALS PVT.LTD | 100/1000 MG | 10 | TABLET XR | 102.86 | 1809307.40 | 2.05% | 2.16% | Y | 10.29 | 10.29 |
| 23 | SITA OD MSR 100/1000 MG TABLET 10 | SITA OD MSR | MACLEODS PHARMACEUTICALS PVT.LTD | 100/1000 MG | 10 | TABLET | 102.86 | 1673737.92 | 1.90% | 1.90% | Y | 10.29 | 10.29 |
| 24 | SITANORM M 100/1000 MG TABLET 15 | SITANORM M | MICRO LABS LTD | 100/1000 MG | 15 | TABLET | 149.29 | 2263684.27 | 2.56% | 2.56% | Y | 9.95 | 9.95 |
| 25 | SITAPRIDE M 100/1000 MG TABLET 15 | SITAPRIDE M | MICRO LABS LTD | 100/1000 MG | 15 | TABLET | 149.29 | 2781571.28 | 3.15% | 3.15% | Y | 9.95 | 9.95 |
| 26 | JANUMET XR CP 100/1000 MG TABLET 14 | JANUMET | MSD PHARMACEUTICALS PRIVATE LTD. | 100/1000 MG | 14 | TABLET | 206.43 | | | | | | |
| 27 | SITA M 100/1000 MG TABLET 10 | SITA M | MSN LABORATORIES LTD | 100/1000 MG | 10 | TABLET | 77.86 | 53334.10 | 0.06% | 0.06% | N | 7.78 | |
| 28 | ISTAMET XR 100/1000 MG TABLET 10 | ISTAMET | SUN PHARMA LABORATORIES LTD. | 100/1000 MG | 10 | TABLET | 103.57 | | | | | | |
| 29 | ISTAMET XR CP 100/1000 MG TABLET 14 | ISTAMET | SUN PHARMA LABORATORIES LTD. | 100/1000 MG | 14 | TABLET | 103.57 | | | | | | |
| 30 | SITARED 100/1000 MG TABLET XR 10 | SITARED | SUN PHARMA LABORATORIES LTD. | 100/1000 MG | 10 | TABLET XR | 103.57 | | | | | | |

| | | | | | | | | | | | | | |
|----|------------------------------------|----------------|------------------------------|-------------|----|-----------|--------|-------------|--------|--------|---|-------|-------|
| 31 | SITAXA M 100/1000 MG TABLET XR 10 | SITAXA M | TORRENT PHARMACEUTICALS LTD. | 100/1000 MG | 10 | TABLET XR | 120.71 | 12288859.54 | 13.92% | 13.92% | Y | 12.07 | 12.07 |
| 32 | STALIX M 100/1000 MG TABLET XR 10 | STALIX M | TORRENT PHARMACEUTICALS LTD. | 100/1000 MG | 10 | TABLET XR | 120.71 | 6012806.52 | 6.81% | 6.81% | Y | 12.07 | 12.07 |
| 33 | SITAWOK M 100/1000 MG TABLET XR 15 | SITAWOK M | WOCKHARDT LTD | 100/1000 MG | 15 | TABLET XR | 139.19 | 176353.73 | 0.20% | 0.20% | N | 9.28 | |
| 34 | SIGLYN M 100/1000 MG TABLET 10 | SIGLYN M | ZYDUS CADILA - ZHL | 100/1000 MG | 10 | TABLET | 121.43 | 90586.78 | 0.10% | 3.52% | Y | 12.14 | 12.14 |
| 35 | SIGLYN M 100/1000 MG TABLET ER 10 | SIGLYN M | ZYDUS CADILA - ZHL | 100/1000 MG | 10 | TABLET ER | 121.43 | 3017292.64 | 3.42% | 3.52% | Y | 12.14 | 12.14 |
| 36 | SITAGLYN M 100/1000 MG TABLET 10 | SITAGLYN M | ZYDUS CADILA - ZHL | 100/1000 MG | 10 | TABLET | 121.43 | 3315281.86 | 3.78% | 3.76% | Y | 12.14 | 12.14 |
| | | Rs. Per Tablet | | | | | | | | | | | |
| | Worked out Retail Price | 13.51 | Excluding GST | | | | | | | | | | |

Computation of Retail Price based on January, 2023 Data under Para 5 of DPCO, 2013
Pioglitazone Hydrochloride IP eq. to Pioglitazone 15 mg

| | | | | | | |
|--|--|--|--|--|--|--------|
| Number of Companies consisting of Market Share of 1% & Above | | | | | | 4 |
| Sum of MAT value considered for price calculation (in Lakhs) | | | | | | 582.97 |
| Sum of PTR per unit considered for price calculation | | | | | | 47.17 |
| Number of Packs considered | | | | | | 12 |
| Average PTR | | | | | | 3.93 |
| Add : 16% Retailer Margin | | | | | | 0.63 |
| Retail Price (without local taxes) | | | | | | 4.56 |
| % Reduction with compared to Highest Price | | | | | | 23.98% |

| | | |
|---------------------------------|--|------|
| Minimum Price (Rs.) | | 1.14 |
| Maximum Price (Rs.) | | 5.17 |
| Average of all considered (Rs.) | | 3.93 |
| Retail Price (Rs.) | | 4.56 |

| S.No. | पैक विवरण Pack Description | छाप BRAND | कंपनी Company | Strength | Pack Size | Unit | TOTAL MAT | 45,64,37,171 | 100% | Brandwise MAT (Ignoring O% MAT) | Qualify (Y/N) Y=Yes N=No | Price per Unit (Rs.) | Price per Unit (Rs.) Considered |
|-------|-------------------------------|-----------------|-----------------------------|----------|-----------|--------|-----------|--------------|----------------|---------------------------------|--------------------------------|----------------------|---------------------------------|
| | | | | | | | PTR(Rs.) | MAT(Rs.) | SKU wise MAT % | | | | |
| 1 | ADGLIM P 15 MG TABLET 10 | ADGLIM P | CADOMED PHARMACEUTICALS | 15 MG | 10 | TABLET | 34.23 | 648773.55 | 0.14% | 0.14% | N | 3.42 | |
| 2 | BETAPRIDE 15 MG TABLET 10 | BETAPRIDE | AVINASH HEALTH PRODUCTS PV | 15 MG | 10 | TABLET | 21.43 | 109609.88 | 0.02% | 0.02% | N | 2.14 | |
| 3 | BIODIB 15 MG TABLET 10 | BIODIB | ZYDUS CADILA - ZHL | 15 MG | 10 | TABLET | 45.25 | 226.25 | 0.00% | 0.00% | N | 4.53 | |
| 4 | DIAGLIT 15 MG TABLET 10 | DIAGLIT | ZYDUS CADILA - ZHL | 15 MG | 10 | TABLET | 40.27 | 25966.85 | 0.01% | 0.01% | N | 4.03 | |
| 5 | GLITARIS 15 MG TABLET 10 | GLITARIS | ERIS LIFESCIENCES LTD | 15 MG | 10 | TABLET | 45.54 | 5120876.39 | 1.12% | 1.12% | Y | 4.55 | 4.55 |
| 6 | HILPIO 15 MG TABLET 10 | HILPIO | HEAL (INDIA) LABORATORIES | 15 MG | 10 | TABLET | 29.33 | 49655.69 | 0.01% | 0.01% | N | 2.93 | |
| 7 | K-PIO 15 MG TABLET 15 | K-PIO | BLUE CROSS LABORATORIES LTD | 15 MG | 15 | TABLET | 23.57 | 10161600.35 | 2.23% | 2.23% | Y | 1.57 | 1.57 |
| 8 | PAZO (SHINE PHARMA) 15 MG TA | PAZO (SHINE PHA | SHINE PHARMACEUTICALS LTD | 15 MG | 10 | TABLET | 17.75 | 62018.50 | 0.01% | 0.01% | N | 1.78 | |
| 9 | PIOGLAR 15 MG TABLET 10 | PIOGLAR | RANBAXY LABORATORIES LTD | 15 MG | 10 | TABLET | 45 | 20097000.00 | 4.40% | 4.40% | Y | 4.50 | 4.50 |
| 10 | PIOGLAZ 15 MG TABLET 10 | PIOGLAZ | EAST WEST PHARMA | 15 MG | 10 | TABLET | 37.86 | 725891.13 | 0.16% | 0.16% | N | 3.79 | |
| 11 | PIOGLUT 15 MG TABLET 10 | PIOGLUT | SUN PHARMA LABORATORIES L | 15 MG | 10 | TABLET | 49.29 | 51429087.03 | 11.27% | 11.27% | Y | 4.93 | 4.93 |
| 12 | PIOGLITAZONE 15 MG TABLET 10 | PIOGLITAZONE | ZYDUS CADILA - ZHL | 15 MG | 10 | TABLET | 8 | 256.00 | 0.00% | 0.00% | N | 0.80 | |
| 13 | PIOHOPE 15 MG TABLET 10 | PIOHOPE | MANKIND PHARMACEUTICALS L | 15 MG | 10 | TABLET | 42.87 | 10010873.79 | 2.19% | 2.19% | Y | 4.29 | 4.29 |
| 14 | PIOKIND 15 MG TABLET 10 | PIOKIND | MANKIND PHARMACEUTICALS L | 15 MG | 10 | TABLET | 42.87 | 18233597.01 | 3.99% | 3.99% | Y | 4.29 | 4.29 |
| 15 | PIOMED 15 MG TABLET 10 | PIOMED | IPCA LABORATORIES PVT LTD. | 15 MG | 10 | TABLET | 51.67 | 12578437.96 | 2.76% | 2.76% | Y | 5.17 | 5.17 |
| 16 | PIONORM 15 MG TABLET 10 | PIONORM | MICRO LABS LTD | 15 MG | 10 | TABLET | 37.86 | 10458516.40 | 2.29% | 2.29% | Y | 3.79 | 3.79 |
| 17 | PIOPAR 15 MG TABLET 15 | PIOPAR | MITOCH PHARMA PVT LTD | 15 MG | 15 | TABLET | 55 | 11050875.00 | 2.42% | 2.42% | Y | 3.67 | 3.67 |
| 18 | PIOPOD 15 MG TABLET 10 | PIOPOD | TORRENT PHARMACEUTICALS L | 15 MG | 10 | TABLET | 43.21 | 9750562.21 | 2.14% | 2.14% | Y | 4.32 | 4.32 |

232

| | | | | | | | | | | | | | |
|----|--------------------------|----------------|------------------------------|-------|----|--------|-------|--------------|--------|--------|---|------|------|
| 19 | PIORUN 15 MG TABLET 10 | PIORUN | JARUN PHARMACEUTICALS | 15 MG | 10 | TABLET | 46.43 | 29483.05 | 0.01% | 0.01% | N | 4.64 | |
| 20 | PIOSAFE 15 MG TABLET 10 | PIOSAFE | ARISTO PHARMACEUTICALS PVT | 15 MG | 10 | TABLET | 46.9 | 3425443.16 | 0.75% | 0.75% | N | 4.69 | |
| 21 | PIOSENZ 15 MG TABLET 10 | PIOSENZ | OPSISCARE LIFESCINCSE PVT LT | 15 MG | 10 | TABLET | 35.71 | 804918.93 | 0.18% | 0.18% | N | 3.57 | |
| 22 | PIOSYS 15 MG TABLET 30 | PIOSYS | SYSTOPIC LABORATORIES LTD-M | 15 MG | 30 | TABLET | 34.29 | 27666361.46 | 6.06% | 6.06% | Y | 1.14 | 1.14 |
| 23 | PIOZ 15 MG TABLET 10 | PIOZ | USV PVT LTD | 15 MG | 10 | TABLET | 49.46 | 260203982.04 | 57.01% | 57.01% | Y | 4.95 | 4.95 |
| 24 | PIOZAR 15 MG TABLET 10 | PIOZAR | SPECTRA THERAPEUTICS PVT. LT | 15 MG | 10 | TABLET | 24.36 | 535725.12 | 0.12% | 0.12% | N | 2.44 | |
| 25 | PIZALET 15 MG TABLET 10 | PIZALET | ICON LIFESCINCES | 15 MG | 10 | TABLET | 26.21 | 62799.16 | 0.01% | 0.01% | N | 2.62 | |
| 26 | PIZONE 15 MG TABLET 10 | PIZONE | ANTHUS PHARMACEUTICALS PV | 15 MG | 10 | TABLET | 16 | 16.00 | 0.00% | 0.00% | N | 1.60 | |
| 27 | POSINORM 15 MG TABLET 10 | POSINORM | MICRO LABS LTD | 15 MG | 10 | TABLET | 25.77 | 25.77 | 0.00% | 0.00% | N | 2.58 | |
| 28 | POZITIV 15 MG TABLET 10 | POZITIV | FRANCO INDIAN PHARMACEUTI | 15 MG | 10 | TABLET | 48.57 | 2889427.96 | 0.63% | 0.63% | N | 4.86 | |
| 29 | PZONE 15 MG TABLET 10 | PZONE | ARETAEUS PHARMACEUTICALS | 15 MG | 10 | TABLET | 22.65 | 302536.05 | 0.07% | 0.07% | N | 2.27 | |
| 30 | ZIPIO 15 MG TABLET 10 | ZIPIO | FDC LTD. | 15 MG | 10 | TABLET | 13.57 | 1628.40 | 0.00% | 0.00% | N | 1.36 | |
| | | Rs. Per Tablet | | | | | | | | | | | |
| | Worked out Retail Price | 4.56 | Excluding GST- | | | | | | | | | | |

Computation of Retail Price based on January, 2023 Data under Para 5 of DPCO, 2013

| | | | | | |
|---|--|--|--|--------|--------|
| Pioglitazone Hydrochloride IP eq. to Pioglitazone 15 mg + Metformin Hydrochloride IP 1000 mg (as sustained release Form). | Number of Companies consisting of Market Share of 1% & Above | | | | 2 |
| | Sum of MAT value considered for price calculation (in Lakhs) | | | | 186.63 |
| Sum of PTR per unit considered for price calculation | | | | 16.71 | |
| Number of Packs considered | | | | 2 | |
| Average PTR | | | | 8.36 | |
| Add : 16% Retailer Margin | | | | 1.34 | |
| Retail Price (without local taxes) | | | | 9.70 | |
| % Reduction with compared to Highest Price | | | | 25.95% | |

| | |
|---------------------------------|-------|
| Minimum Price (Rs.) | 5.42 |
| Maximum Price (Rs.) | 11.29 |
| Average of all considered (Rs.) | 8.36 |
| Retail Price (Rs.) | 9.7 |

| S.No. | पैक विवरण Pack Description | ब्रांड BRAND | कंपनी Company | Strength | Pack Size | Unit | TOTAL MAT | 1,98,63,500 | 100% | M3 | | | |
|-------|---------------------------------------|-----------------|--------------------------------|------------|-----------|--------|-----------|-------------|-------------------|--|--------------------------------|----------------------------|---------------------------------------|
| | | | | | | | PTR(Rs.) | MAT(Rs.) | SKU wise MAT % | Brandwise MAT (ignoring 0% MAT) | Quality (Y/N) Y=Yes N=No | Price per Unit (Rs.) | Price per Unit (Rs.) Considered |
| 1 | GLITARIS M FORTE 15/1000 MG TABLET 10 | GLITARIS M | ERIS LIFESCIENCES LTD | 15/1000 MG | 10 | TABLET | 63.26 | 317.15 | 0.00% | 0.00% | N | 6.33 | |
| 2 | MOPADAY FORTE 15/1000 MG TABLET 10 | MOPADAY | WOCKHARDT LTD | 15/1000 MG | 10 | TABLET | 112.86 | 19320688.62 | 98.26% | 98.26% | Y | 11.29 | 11.29 |
| 3 | PIOZAR MF FORTE 15/1000 MG TABLET 10 | PIOZAR MF | SPECTRA THERAPEUTICS PVT. LTD. | 15/1000 MG | 10 | TABLET | 54.22 | 342494.71 | 1.74% | 1.74% | Y | 5.42 | 5.42 |
| | | Rs. Per Tablet | | | | | | | | | | | |
| | Worked out Retail Price | 9.70 | Excluding GST | | | | | | | | | | |

407

Computation of Retail Price based on January, 2023 Data under Para 5 of DPCO, 2013

| | | | | | |
|--|--|--|--|--|----------|
| Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100 mg | Number of Companies consisting of Market Share of 1% & Above | | | | 19 |
| | Sum of MAT value considered for price calculation (in Lakhs) | | | | 2,086.86 |
| | Sum of PTR per unit considered for price calculation | | | | 224.58 |
| | Number of Packs considered | | | | 24 |
| | Average PTR | | | | 9.36 |
| | Add : 16% Retailer Margin | | | | 1.50 |
| | Retail Price (without local taxes) | | | | 10.86 |
| | % Reduction with compared to Highest Price | | | | 21.54% |

| | | |
|---------------------------------|--|-------|
| Minimum Price (Rs.) | | 5.71 |
| Maximum Price (Rs.) | | 11.93 |
| Average of all considered (Rs.) | | 9.36 |
| Retail Price (Rs.) | | 10.86 |

| S.No. | पैक विवरण Pack Description | छाप BRAND | कंपनी Company | Strength | Pack Size | Unit | TOTAL MAT | 22,54,23,919 | 100% | M3 | | | Price per Unit (Rs.) | Price per Unit (Rs.) Considered |
|-------|-------------------------------|--------------|-------------------------------|----------|-----------|--------|-----------|--------------|----------------|---------------------------------|--------------------------|-------|----------------------|---------------------------------|
| | | | | | | | PTR(Rs.) | MAT(Rs.) | SKU wise MAT % | Brandwise MAT (ignoring 0% MAT) | Quality (Y/N) Y=Yes N=No | | | |
| 1 | SIAGLIDE 100 MG TABLET 15 | SIAGLIDE | ABBOTT HEALTHCARE PVT. LTD | 100 MG | 15 | TABLET | 178.93 | 4543390.56 | 2.02% | 2.02% | Y | 11.93 | 11.93 | |
| 2 | ACSITA 100 MG TABLET 10 | ACSITA | ACMEDIX PHARMA LLP | 100 MG | 10 | TABLET | 49.3 | 43720.23 | 0.02% | 0.02% | N | 4.93 | 4.93 | |
| 3 | SITAMAX 100 MG TABLET 10 | SITAMAX | AJANTA PHARMA LTD | 100 MG | 10 | TABLET | 92.5 | 852480.00 | 0.38% | 0.38% | N | 9.25 | 9.25 | |
| 4 | SITAPAZ 100 MG TABLET 10 | SITAPAZ | AKESIS PHARMA (P) LTD | 100 MG | 10 | TABLET | 92.14 | 1158351.86 | 0.51% | 0.51% | N | 9.21 | 9.21 | |
| 5 | SITALEMBIC 100 MG TABLET 15 | SITALEMBIC | ALEMBIC LTD | 100 MG | 15 | TABLET | 139.29 | 5490533.22 | 2.44% | 2.44% | Y | 9.29 | 9.29 | |
| 6 | ALSITA 100 MG TABLET 10 | ALSITA | ALKEM LABORATORIES LTD. | 100 MG | 10 | TABLET | 70.71 | 13162949.34 | 5.84% | 5.84% | Y | 7.07 | 7.07 | |
| 7 | SITALONG 100 MG TABLET 15 | SITALONG | ALTEUS BIOGENICS PVT.LTD. | 100 MG | 15 | TABLET | 182.14 | 363005.02 | 0.16% | 0.16% | N | 12.14 | 12.14 | |
| 8 | SITAGLIP 100 MG TABLET 10 | SITAGLIP | ANTHEM BIOPHARMA PVT LTD | 100 MG | 10 | TABLET | 107.14 | 534414.32 | 0.24% | 0.24% | N | 10.71 | 10.71 | |
| 9 | SIDIA 100 MG TABLET 10 | SIDIA | APRICA HEALTHCARE PVT LTD | 100 MG | 10 | TABLET | 107.14 | 477844.40 | 0.21% | 0.21% | N | 10.71 | 10.71 | |
| 10 | SITAGLO 100 MG TABLET 15 | SITAGLO | ARISTO PHARMACEUTICALS PVT.L | 100 MG | 15 | TABLET | 171.43 | 6709770.20 | 2.98% | 2.98% | Y | 11.43 | 11.43 | |
| 11 | TERGRA 100 MG TABLET 10 | TERGRA | BIOCON LTD | 100 MG | 10 | TABLET | 103.57 | 332252.56 | 0.15% | 0.15% | N | 10.36 | 10.36 | |
| 12 | JANKEY 100 MG TABLET 15 | JANKEY | CADILA PHARMACEUTICALS LTD | 100 MG | 15 | TABLET | 144.64 | 722332.16 | 0.32% | 0.32% | N | 9.84 | 9.84 | |
| 13 | SITENALI 100 MG TABLET 15 | SITENALI | CADILA PHARMACEUTICALS LTD | 100 MG | 15 | TABLET | 144.64 | 921212.16 | 0.41% | 0.41% | N | 9.84 | 9.84 | |
| 14 | SITACIP 100 MG TABLET 10 | SITACIP | CIPLA LTD. | 100 MG | 10 | TABLET | 92.14 | 6558934.17 | 2.91% | 2.91% | Y | 9.21 | 9.21 | |
| 15 | SITABITE 100 MG TABLET 10 | SITABITE | CORONA | 100 MG | 10 | TABLET | 70.71 | 8100465.89 | 3.59% | 3.59% | Y | 7.07 | 7.07 | |
| 16 | STIG 100 MG TABLET 15 | STIG | DR. REDDYS LABORATORIES LTD | 100 MG | 15 | TABLET | 117.86 | 3003897.82 | 1.33% | 1.33% | Y | 7.86 | 7.86 | |
| 17 | EMSITA 100 MG TABLET 10 | EMSITA | EMCURE PHARMACEUTICALS LTD | 100 MG | 10 | TABLET | 107.07 | 4357213.65 | 1.93% | 1.93% | Y | 10.71 | 10.71 | |
| 18 | GLURA 100 MG TABLET 10 | GLURA | ERIS LIFESCIENCES LTD | 100 MG | 10 | TABLET | 107.14 | 13435034.58 | 5.96% | 5.96% | Y | 10.71 | 10.71 | |
| 19 | SITDC 100 MG TABLET 10 | SITDC | FDC LTD. | 100 MG | 10 | TABLET | 85.71 | 178962.48 | 0.08% | 0.08% | N | 8.57 | 8.57 | |
| 20 | CTASORIN 100 MG TABLET 10 | CTASORIN | FUSION HEALTHCARE PVT LTD | 100 MG | 10 | TABLET | 99.29 | 518095.22 | 0.23% | 0.23% | N | 9.93 | 9.93 | |
| 21 | SITAZIT 100 MG TABLET 10 | SITAZIT | GLENMARK PHARMACEUTICALS | 100 MG | 10 | TABLET | 103.57 | 10393456.64 | 4.61% | 4.61% | Y | 10.36 | 10.36 | |
| 22 | QSITA 100 MG TABLET 10 | QSITA | HBC LIFESCIENCES PVT LTD | 100 MG | 10 | TABLET | 57.14 | 1995671.64 | 0.89% | 0.89% | N | 5.71 | 5.71 | |
| 23 | SITOZA 100 MG TABLET 10 | SITOZA | HETERO HEALTHCARE LTD | 100 MG | 10 | TABLET | 71.43 | 119203.17 | 0.05% | 0.05% | N | 7.14 | 7.14 | |
| 24 | SPIKERID 100 MG TABLET 10 | SPIKERID | INDCHEMIE HEALTH SPECIALITIES | 100 MG | 10 | TABLET | 70.71 | 43910.91 | 0.02% | 0.02% | N | 7.07 | 7.07 | |

| | | | | | | | | | | | | | |
|-----|-----------------------------|----------------|------------------------------|--------|----|--------|--------|-------------|-------|-------|---|-------|-------|
| 25 | IGNALIS 100 MG TABLET 10 | IGNALIS | INTAS PHARMACEUTICALS LTD | 100 MG | 10 | TABLET | 96.43 | 8528847.78 | 3.78% | 3.78% | Y | 9.64 | 9.64 |
| 26 | SITARA 100 MG TABLET 10 | SITARA | INTAS PHARMACEUTICALS LTD | 100 MG | 10 | TABLET | 96.43 | 13072436.52 | 5.80% | 5.80% | Y | 9.64 | 9.64 |
| 27 | SUITGLIP 100 MG TABLET 10 | SUITGLIP | IPCA LABORATORIES PVT LTD. | 100 MG | 10 | TABLET | 85.71 | 198761.49 | 0.09% | 0.09% | N | 8.57 | |
| 28 | JSITA 100 MG TABLET 10 | JSITA | JARUN PHARMACEUTICALS | 100 MG | 10 | TABLET | 92.14 | 5159.84 | 0.00% | 0.00% | N | 9.21 | |
| 29 | SITACOSE 100 MG TABLET 10 | SITACOSE | JB CHEMICALS | 100 MG | 10 | TABLET | 85.72 | 967178.76 | 0.43% | 0.43% | N | 8.57 | |
| 30 | SITAHENZ 100 MG TABLET 10 | SITAHENZ | LA RENON | 100 MG | 10 | TABLET | 105.71 | 8446651.84 | 3.75% | 3.75% | Y | 10.57 | 10.57 |
| 31 | SUGARAY 100 MG TABLET 15 | SUGARAY | LLOYD HEALTHCARE PVT.LTD | 100 MG | 15 | TABLET | 127.5 | 725220.00 | 0.32% | 0.32% | N | 8.50 | |
| 32 | LUPISIT 100 MG TABLET 10 | LUPISIT | LUPIN LTD | 100 MG | 10 | TABLET | 85.71 | 10965823.11 | 4.86% | 4.86% | Y | 8.57 | 8.57 |
| 33 | MACSITA 100 MG TABLET 10 | MACSITA | MACLEODS PHARMACEUTICALS P | 100 MG | 10 | TABLET | 75.71 | 5334678.02 | 2.37% | 2.37% | Y | 7.57 | 7.57 |
| 34 | SITA OD 100 MG TABLET 10 | SITA OD | MACLEODS PHARMACEUTICALS P | 100 MG | 10 | TABLET | 75.71 | 11088410.89 | 4.92% | 4.92% | Y | 7.57 | 7.57 |
| 35 | SITACCLASS 100 MG TABLET 10 | SITACCLASS | MACLEODS PHARMACEUTICALS P | 100 MG | 10 | TABLET | 75.71 | 141501.99 | 0.06% | 0.06% | N | 7.57 | |
| 36 | SITADAY 100 MG TABLET 15 | SITADAY | MANKIND PHARMACEUTICALS LT | 100 MG | 15 | TABLET | 148.93 | 6578833.82 | 2.92% | 2.92% | Y | 9.93 | 9.93 |
| 37 | CORSITA 100 MG TABLET 10 | CORSITA | MEDLEY PHARMACEUTICALS | 100 MG | 10 | TABLET | 113.57 | 2061863.35 | 0.91% | 0.91% | N | 11.36 | |
| 38 | SITANORM 100 MG TABLET 15 | SITANORM | MICRO LABS LTD | 100 MG | 15 | TABLET | 127.86 | 6293269.20 | 2.79% | 2.79% | Y | 8.52 | 8.52 |
| 39 | SITAPRIDE 100 MG TABLET 15 | SITAPRIDE | MICRO LABS LTD | 100 MG | 15 | TABLET | 127.86 | 7287764.28 | 3.23% | 3.23% | Y | 8.52 | 8.52 |
| 40 | JANUVIA 100 MG TABLET 15 | JANUVIA | MSD PHARMACEUTICALS PRIVAT | 100 MG | 15 | TABLET | 192.86 | | | | | | |
| 41 | JANUVIA 100 MG TABLET 7 | JANUVIA | MSD PHARMACEUTICALS PRIVAT | 100 MG | 7 | TABLET | 192.86 | | | | | | |
| 42 | SITA (MSN) 100 MG TABLET 10 | SITA (MSN) | MSN LABORATORIES LTD | 100 MG | 10 | TABLET | 99.29 | 138910.97 | 0.08% | 0.06% | N | 9.93 | |
| 43 | SITANAT 100 MG TABLET 10 | SITANAT | NATCO PHARMA LTD | 100 MG | 10 | TABLET | 113.57 | 1144217.75 | 0.51% | 0.51% | N | 11.36 | |
| 44 | GLUPCRIN 100 MG TABLET 15 | GLUPCRIN | PRIMUS REMEDIES PVT LTD | 100 MG | 15 | TABLET | 138.75 | 843877.50 | 0.37% | 0.37% | N | 9.25 | |
| 45 | 6F1C 100 MG TABLET 15 | 6F1C | SINSAN PHARMACEUTICALS | 100 MG | 15 | TABLET | 250 | 226750.00 | 0.10% | 0.10% | N | 16.67 | |
| 46 | ISTAVEL 100 MG TABLET 7 | ISTAVEL | SUN PHARMA LABORATORIES LT | 100 MG | 7 | TABLET | 64.75 | | | | | | |
| 47 | SITARED 100 MG TABLET 10 | SITARED | SUN PHARMA LABORATORIES LT | 100 MG | 10 | TABLET | 64.75 | | | | | | |
| 48 | SITARED 100 MG TABLET 7 | SITARED | SUN PHARMA LABORATORIES LT | 100 MG | 7 | TABLET | 64.75 | | | | | | |
| 49 | SITASYS 100 MG TABLET 10 | SITASYS | SYSTOPIC LABORATORIES LTD-ME | 100 MG | 10 | TABLET | 56.43 | 348279.95 | 0.15% | 0.15% | N | 5.64 | |
| 50 | SITALENT 100 MG TABLET 10 | SITALENT | TALENT INDIA | 100 MG | 10 | TABLET | 127.86 | 158546.40 | 0.07% | 0.07% | N | 12.79 | |
| 51 | SITAXA 100 MG TABLET 15 | SITAXA | TORRENT PHARMACEUTICALS LT | 100 MG | 15 | TABLET | 159.64 | 19334798.60 | 8.58% | 8.58% | Y | 10.64 | 10.64 |
| 52 | STALIX 100 MG TABLET 15 | STALIX | TORRENT PHARMACEUTICALS LT | 100 MG | 15 | TABLET | 159.64 | 18253237.60 | 8.10% | 8.10% | Y | 10.64 | 10.64 |
| 53 | SITASON 100 MG TABLET 10 | SITASON | UNISON PHARMACEUTICALS | 100 MG | 10 | TABLET | 46.43 | 392983.52 | 0.17% | 0.17% | N | 4.64 | |
| 54 | SITAWOK 100 MG TABLET 15 | SITAWOK | WOCKHARDT LTD | 100 MG | 15 | TABLET | 85.61 | 5212536.07 | 2.31% | 2.31% | Y | 5.71 | 5.71 |
| 55 | SITASAR 100 MG TABLET 10 | SITASAR | WONSET HEALTH CARE PRIVATE I | 100 MG | 10 | TABLET | 92.86 | 148576.00 | 0.07% | 0.07% | N | 9.28 | |
| -56 | ZENSITA 100 MG TABLET 10 | ZENSITA | ZUVENTUS HEALTHCARE LTD | 100 MG | 10 | TABLET | 92.5 | 975135.00 | 0.43% | 0.43% | N | 9.25 | |
| 57 | SIGLYN 100 MG TABLET 10 | SIGLYN | ZYDUS CADILA - ZHL | 100 MG | 10 | TABLET | 107.14 | 6235548.00 | 2.77% | 2.77% | Y | 10.71 | 10.71 |
| 58 | SITAGLYN 100 MG TABLET 10 | SITAGLYN | ZYDUS CADILA - ZHL | 100 MG | 10 | TABLET | 107.14 | 6287618.04 | 2.79% | 2.79% | Y | 10.71 | 10.71 |
| | | Rs. Per Tablet | | | | | | | | | | | |
| | Worked out Retail Price | 10.86 | Excluding GST | | | | | | | | | | |

Computation of Retail Price based on January, 2023 Data under Para 5 of DPCO, 2013

Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100 mg + Metformin Hydrochloride IP 500 mg (as sustained release Form)

| | | | | | |
|--|--|--|--|--|--------|
| Number of Companies consisting of Market Share of 1% & Above | | | | | 1 |
| Sum of MAT value considered for price calculation (in Lakhs) | | | | | 123.37 |
| Sum of PTR per unit considered for price calculation | | | | | 160.83 |
| Number of Packs considered | | | | | 15 |
| Average PTR | | | | | 10.72 |
| Add : 16% Retailer Margin | | | | | 1.72 |
| Retail Price (without local taxes) | | | | | 12.44 |
| % Reduction with compared to Highest Price | | | | | 16.84% |

| | | |
|---------------------------------|--|-------|
| Minimum Price (Rs.) | | 8.86 |
| Maximum Price (Rs.) | | 12.86 |
| Average of all considered (Rs.) | | 10.72 |
| Retail Price (Rs.) | | 12.44 |

| S.No. | पैक विवरण Pack Description | ब्रांड BRAND | कंपनी Company | Strength | Pack Size | Unit | TOTAL MAT | 6,68,33,500 | 100% | M3 | | Price per Unit (Rs.) Considered | |
|-------|---------------------------------------|-----------------|----------------------------------|------------|-----------|-----------|-----------|-------------|-------------------|--|--------------------------------|---------------------------------------|----------------------------|
| | | | | | | | PTR(Rs.) | MAT(Rs.) | SKU wise MAT % | Brandwise MAT % (Ignoring 0% MAT) | Qualify (Y/N) Y=Yes N=No | | Price per Unit (Rs.) |
| 1 | SITALEMBIC M 100/500 MG TABLET SR 15 | SITALEMBIC M | ALEMBIC LTD | 100/500 MG | 15 | TABLET SR | 139.29 | 492668.73 | 0.74% | 0.74% | N | 9.28 | |
| 2 | ALSITA M 100/500 MG TABLET 10 | ALSITA M | ALKEM LABORATORIES LTD. | 100/500 MG | 10 | TABLET | 92.14 | 12337453.86 | 18.45% | 18.46% | Y | 9.21 | 9.21 |
| 3 | SITAGLO MSR 100/500 MG TABLET 15 | SITAGLO MSR | ARISTO PHARMACEUTICALS PVT.LTD | 100/500 MG | 15 | TABLET | 139.22 | 410098.74 | 0.61% | 0.61% | N | 9.21 | |
| 4 | SITACIP M 100/500 MG TABLET 10 | SITACIP M | CIPLA LTD. | 100/500 MG | 10 | TABLET | 106.43 | 4269213.64 | 6.39% | 6.39% | Y | 10.64 | 10.64 |
| 5 | SITABITE M 100/500 MG TABLET SR 10 | SITABITE M | CORONA | 100/500 MG | 10 | TABLET SR | 106.43 | 1109532.75 | 1.66% | 1.66% | Y | 10.64 | 10.64 |
| 6 | GLURA M 100/500 MG TABLET XR 15 | GLURA M | ERIS LIFESCIENCES LTD | 100/500 MG | 15 | TABLET XR | 171.43 | 289202.41 | 0.43% | 0.43% | N | 11.43 | |
| 7 | CTASORIN M 100/500 MG TABLET 10 | CTASORIN M | FUSION HEALTHCARE PVT LTD | 100/500 MG | 10 | TABLET | 128.57 | 2061491.38 | 3.08% | 3.08% | Y | 12.86 | 12.86 |
| 8 | SITAZIT M 100/500 MG TABLET ER 10 | SITAZIT M | GLENMARK PHARMACEUTICALS LTD. | 100/500 MG | 10 | TABLET ER | 127.86 | 6434298.78 | 9.63% | 9.63% | Y | 12.79 | 12.79 |
| 9 | QSITA M 100/500 MG TABLET SR 10 | QSITA M | HBC LIFESCIENCES PVT LTD | 100/500 MG | 10 | TABLET SR | 78.57 | 95541.12 | 0.14% | 0.14% | N | 7.86 | |
| 10 | IGNALIS M 100/500 MG TABLET 10 | IGNALIS M | JINTAS PHARMACEUTICALS LTD | 100/500 MG | 10 | TABLET | 103.57 | 8812874.87 | 13.19% | 13.19% | Y | 10.36 | 10.36 |
| 11 | SITARA-M 100/500 MG TABLET 10 | SITARA-M | JINTAS PHARMACEUTICALS LTD | 100/500 MG | 10 | TABLET | 103.57 | 7592509.56 | 11.36% | 11.36% | Y | 10.36 | 10.36 |
| 12 | SUITGLIP M 100/500 MG TABLET XR 10 | SUITGLIP M | IPCA LABORATORIES PVT LTD. | 100/500 MG | 10 | TABLET XR | 100 | 162500.00 | 0.24% | 0.24% | N | 10.00 | |
| 13 | ISITA M 100/500 MG TABLET 10 | ISITA M | JARUN PHARMACEUTICALS | 100/500 MG | 10 | TABLET | 132.14 | 23917.34 | 0.04% | 0.04% | N | 13.21 | |
| 14 | SITAHENZ M OD 15 100/500 MG TABLET 10 | SITAHENZ M OD | LA RENON | 100/500 MG | 10 | TABLET | 127.14 | 362730.42 | 0.54% | 0.54% | N | 12.71 | |
| 15 | MACSITA M 100/500 MG TABLET XR 10 | MACSITA M | MACLEODS PHARMACEUTICALS PVT.LTD | 100/500 MG | 10 | TABLET XR | 88.57 | 2200610.22 | 3.29% | 3.29% | Y | 8.86 | 8.86 |
| 16 | SITA OD MSR 100/500 MG TABLET 10 | SITA OD MSR | MACLEODS PHARMACEUTICALS PVT.LTD | 100/500 MG | 10 | TABLET | 88.57 | 2127717.11 | 3.18% | 3.18% | Y | 8.86 | 8.86 |
| 17 | SITANORM M 100/500 MG TABLET 15 | SITANORM M | MICRO LABS LTD | 100/500 MG | 15 | TABLET | 138.57 | 176538.18 | 0.26% | 0.26% | N | 9.24 | |
| 18 | SITAPRIDE M 100/500 MG TABLET 15 | SITAPRIDE M | MICRO LABS LTD | 100/500 MG | 15 | TABLET | 138.57 | 3416720.49 | 5.11% | 5.11% | Y | 9.24 | 9.24 |
| 19 | ISTAMET XR 100/500 MG TABLET 10 | ISTAMET | SUN PHARMA LABORATORIES LTD. | 100/500 MG | 10 | TABLET | 96.43 | | | | | | |
| 20 | SITARED M 100/500 MG TABLET XR 10 | SITARED M | SUN PHARMA LABORATORIES LTD. | 100/500 MG | 10 | TABLET XR | 96.43 | | | | | | |
| 21 | SITAXA M 100/500 MG TABLET XR 10 | SITAXA M | TORRENT PHARMACEUTICALS LTD. | 100/500 MG | 10 | TABLET XR | 113.57 | 3607437.48 | 5.40% | 5.40% | Y | 11.36 | 11.36 |
| 22 | STALIX M 100/500 MG TABLET XR 10 | STALIX M | TORRENT PHARMACEUTICALS LTD. | 100/500 MG | 10 | TABLET XR | 113.57 | 3226069.42 | 4.83% | 4.83% | Y | 11.36 | 11.36 |
| 23 | SITAWOK M 100/500 MG TABLET XR 10 | SITAWOK M | WOCKHARDT LTD | 100/500 MG | 10 | TABLET XR | 128.46 | 45346.38 | 0.07% | 0.07% | N | 12.85 | |
| 24 | SIGLYN M 100/500 MG TABLET 10 | SIGLYN M | ZYDUS CADILA - ZHL | 100/500 MG | 10 | TABLET | 114.29 | 111889.91 | 0.17% | 6.14% | Y | 11.43 | 11.43 |
| 25 | SIGLYN M 100/500 MG TABLET ER 10 | SIGLYN M | ZYDUS CADILA - ZHL | 100/500 MG | 10 | TABLET ER | 114.29 | 3992606.86 | 5.97% | 6.14% | Y | 11.43 | 11.43 |
| 26 | SITAGLYN M 100/500 MG TABLET 10 | SITAGLYN M | ZYDUS CADILA - ZHL | 100/500 MG | 10 | TABLET | 114.29 | 3474530.29 | 5.20% | 5.20% | Y | 11.43 | 11.43 |
| | | Rs. Per Tablet | | | | | | | | | | | |
| | Worked out Retail Price | 12.44 | Excluding GST | | | | | | | | | | |

237

Computation of Retail Price based on January, 2023 Data under Para 5 of DPCO, 2013

| | | | | | |
|---|--|--|--|--------|--------|
| Pioglitazone Hydrochloride IP eq. to Pioglitazone 15 mg + Metformin Hydrochloride IP 500 mg (as sustained release Form) | Number of Companies consisting of Market Share of 1% & Above | | | | 4 |
| | Sum of MAT value considered for price calculation (in Lakhs) | | | | 427.76 |
| | Sum of PTR per unit considered for price calculation | | | | 87.38 |
| | Number of Packs considered | | | | 13 |
| | Average PTR | | | | 6.72 |
| | Add : 16% Retailer Margin | | | | 1.08 |
| | Retail Price (without local taxes) | | | | 7.80 |
| % Reduction with compared to Highest Price | | | | 26.88% | |

| | |
|---------------------------------|------|
| Minimum Price (Rs.) | 2.38 |
| Maximum Price (Rs.) | 9.19 |
| Average of all considered (Rs.) | 6.72 |
| Retail Price (Rs.) | 7.8 |

| S.No. | पैक विवरण Pack Description | उप BRAND | कंपनी Company | Strength | Pack Size | Unit | TOTALMAT | 37,34,25,974 | 100% | M3 | | | |
|-------|-------------------------------------|----------------|---------------------------------------|-----------|-----------|-----------|----------|--------------|-------------------|--|--------------------------------|----------------------------|---------------------------------------|
| | | | | | | | PTR(Rs.) | MAT(Rs.) | SKU wise MAT % | Brandwise MAT (Ignoring 0% MAT) | Qualify (Y/N) Y=Yes N=No | Price per Unit (Rs.) | Price per Unit (Rs.) Considered |
| 1 | CETAPIN P 15/500 MG TABLET 15 | CETAPIN P | SANOI INDIA LTD. | 15/500 MG | 15 | TABLET | 89.43 | 117779.31 | 0.03% | 0.03% | N | 5.88 | |
| 2 | GLUTARIS M 15/500 MG TABLET 10 | GLUTARIS M | ERIS LIFESCIENCES LTD | 15/500 MG | 10 | TABLET | 63.26 | 6309601.41 | 1.69% | 1.69% | Y | 6.33 | 6.33 |
| 3 | GLUCONORM-P 15/500 MG TABLET ER 10 | GLUCONORM-P | LUPIN LTD | 15/500 MG | 10 | TABLET ER | 87.64 | 33172943.63 | 8.88% | 8.88% | Y | 8.76 | 8.76 |
| 4 | GLYCIPHAGE P 15/500 MG TABLET SR 10 | GLYCIPHAGE P | FRANCO INDIAN PHARMACEUTICALS PVT LTD | 15/500 MG | 10 | TABLET SR | 63.39 | 13563674.88 | 3.63% | 3.63% | Y | 6.34 | 6.34 |
| 5 | K-PIO M 15/500 MG TABLET SR 15 | K-PIO M | BLUE CROSS LABORATORIES LTD | 15/500 MG | 15 | TABLET SR | 35.71 | 5527795.67 | 1.48% | 1.48% | Y | 2.38 | 2.38 |
| 6 | MEFOMIN P 15/500 MG TABLET 10 | MEFOMIN P | MACLEODS PHARMACEUTICALS PVT.LTD | 15/500 MG | 10 | TABLET | 46.48 | 7018.48 | 0.00% | 0.00% | N | 4.65 | |
| 7 | MOPADAY 15/500 MG TABLET 15 | MOPADAY | WOCKHARDT LTD | 15/500 MG | 15 | TABLET | 122.14 | 7308323.54 | 1.86% | 1.98% | Y | 8.14 | 8.14 |
| 8 | PIO-M 15/500 MG TABLET 15 | PIO-M | SYSTOPIC LABORATORIES LTD-MEM | 15/500 MG | 15 | TABLET | 46.07 | 9234961.85 | 2.47% | 2.47% | Y | 3.07 | 3.07 |
| 9 | PIOGLAR MF 15/500 MG TABLET 10 | PIOGLAR MF | RANBAXY LABORATORIES LTD | 15/500 MG | 10 | TABLET | 85.71 | 1119564.63 | 0.30% | 0.30% | N | 8.57 | |
| 10 | PIOGLAZ M 15/500 MG TABLET 10 | PIOGLAZ M | EAST WEST PHARMA | 15/500 MG | 10 | TABLET | 44.72 | 62697.44 | 0.02% | 0.02% | N | 4.47 | |
| 11 | PIOGLUT MF 15/500 MG TABLET ER 10 | PIOGLUT MF | SUN PHARMA LABORATORIES LTD. | 15/500 MG | 10 | TABLET ER | 85.71 | 39803794.17 | 10.66% | 10.66% | Y | 8.57 | 8.57 |
| 12 | PIOHOPE M 15/500 MG TABLET 10 | PIOHOPE M | MANKIND PHARMACEUTICALS LTD. | 15/500 MG | 10 | TABLET | 49.44 | 4601331.36 | 1.23% | 1.23% | Y | 4.94 | 4.94 |
| 13 | PIOKIND-M 15/500 MG TABLET 10 | PIOKIND-M | MANKIND PHARMACEUTICALS LTD. | 15/500 MG | 10 | TABLET | 59.81 | 14026463.34 | 3.76% | 3.76% | Y | 5.98 | 5.98 |
| 14 | PIOLET-M 15/500 MG TABLET 10 | PIOLET-M | INTAS PHARMACEUTICALS LTD | 15/500 MG | 10 | TABLET | 42.49 | 77459.27 | 0.02% | 0.02% | N | 4.25 | |
| 15 | PIOMED M 15/500 MG TABLET 10 | PIOMED M | IPCA LABORATORIES PVT LTD. | 15/500 MG | 10 | TABLET | 76.74 | 8685433.20 | 2.33% | 2.33% | Y | 7.67 | 7.67 |
| 16 | PIONORM M 15/500 MG TABLET SR 10 | PIONORM M | MICRO LABS LTD | 15/500 MG | 10 | TABLET SR | 77.86 | 7877436.51 | 2.11% | 2.11% | Y | 7.79 | 7.79 |
| 17 | PIOPOD MF 15/500 MG TABLET 10 | PIOPOD MF | TORRENT PHARMACEUTICALS LTD. | 15/500 MG | 10 | TABLET | 82.21 | 7295611.33 | 1.95% | 1.95% | Y | 8.22 | 8.22 |
| 18 | PIORUN M 15/500 MG TABLET 10 | PIORUN M | JARUN PHARMACEUTICALS | 15/500 MG | 10 | TABLET | 65.71 | 120559.21 | 0.03% | 0.03% | N | 6.57 | |
| 19 | PIOSAFE MF 15/500 MG TABLET 10 | PIOSAFE MF | ARISTO PHARMACEUTICALS PVT.LTD | 15/500 MG | 10 | TABLET | 71.14 | 3129802.56 | 0.84% | 0.84% | N | 7.11 | |
| 20 | PIOTAB M 15/500 MG TABLET 10 | PIOTAB M | MARC PHARMA | 15/500 MG | 10 | TABLET | 42.86 | 28116.16 | 0.01% | 0.01% | N | 4.29 | |
| 21 | PIOZ MF 15/500 MG TABLET 10 | PIOZ MF | USV PVT LTD | 15/500 MG | 10 | TABLET | 91.9 | 210342250.54 | 56.33% | 56.33% | Y | 9.19 | 9.19 |
| 22 | PIOZAR MF 15/500 MG TABLET 10 | PIOZAR MF | SPECTRA THERAPEUTICS PVT. LTD. | 15/500 MG | 10 | TABLET | 42.43 | 1013352.98 | 0.27% | 0.27% | N | 4.24 | |
| | | Rs. Per Tablet | | | | | | | | | | | |
| | Worked out Retail Price | 7.80 | Excluding GST | | | | | | | | | | |

238

Computation of Retail Price based on January, 2023 Data under Para 5 of DPCO, 2013

Subject: Retail price fixation under Para 5 of DPCO, 2013 – Each film coated bilayered tablet contains: Dapagliflozin + Metformin

| | |
|--|--------|
| Number of Companies consisting of Market Share of 1% & Above | 15 |
| Sum of MAT value considered for price calculation (in Lakhs) | 369.06 |
| Sum of PTR per unit considered for price calculation | 134.86 |
| Number of Packs considered | 19 |
| Average PTR | 7.10 |
| Add : 16% Retailer Margin | 1.14 |
| Retail Price (without local taxes) | 8.24 |
| % Reduction with compared to Highest Price | 41.18% |

| | |
|---------------------------------|-------|
| Minimum Price (Rs.) | 5.83 |
| Maximum Price (Rs.) | 12.07 |
| Average of all considered (Rs.) | 7.10 |
| Retail Price (Rs.) | 8.24 |

| S.No. | पैक विवरण Pack Description | ब्रांड BRAND | कंपनी Company | Strength | Pack Size | Unit | TOTAL MAT | 3,79,24,564 | 100% | M3 | | | Price per Unit (Rs.) | Price per Unit (Rs.) Considered |
|-------|--------------------------------------|-----------------|----------------------------------|-----------|-----------|-----------|-----------|-------------|-------------------|--|--------------------------------|----------------------------|-------------------------|---------------------------------------|
| | | | | | | | PTR(Rs.) | MAT(Rs.) | SKU wise MAT % | Brandwise o MAT (ignoring 0% MAT) | Quality (Y/N) Y=Yes N=No | Price per Unit (Rs.) | | |
| 1 | GLEDEPA MET 5/1000 MG TABLET IR 14 | GLEDEPA MET | ABBOTT HEALTHCARE PVT. LTD | 5/1000 MG | 14 | TABLET IR | 312.14 | | | | | | | |
| 2 | VOAGE M 5/1000 MG TABLET 10 | VOAGE M | ALEMBIC LTD | 5/1000 MG | 10 | TABLET | 64.29 | 1398371.79 | 3.69% | 3.69% | Y | 6.43 | 6.43 | |
| 3 | DAPANORM M FORTE 5/1000 MG TABLET 10 | DAPANORM M | ALKEM LABORATORIES LTD. | 5/1000 MG | 10 | TABLET | 64.96 | 4324257.28 | 11.40% | 11.40% | Y | 6.50 | 6.50 | |
| 4 | DAPRICA M FORTE 5/1000 MG TABLET 10 | DAPRICA M | APRICA HEALTHCARE PVT LTD | 5/1000 MG | 10 | TABLET | 66.43 | 120703.31 | 0.32% | 0.32% | N | 6.64 | | |
| 5 | XIGDUO IR 5/1000 MG TABLET 14 | XIGDUO IR | ASTRAZENECA PHARMA INDIA LTD | 5/1000 MG | 14 | TABLET | 235 | | | | | | | |
| 6 | DAPABITE M 5/1000 MG TABLET 10 | DAPABITE M | CORONA | 5/1000 MG | 10 | TABLET | 66.8 | 1489439.60 | 3.93% | 3.93% | Y | 6.68 | 6.68 | |
| 7 | DAPLO MF 5/1000 MG TABLET 10 | DAPLO MF | DR. REDDYS LABORATORIES LTD | 5/1000 MG | 10 | TABLET | 114.29 | 1457083.21 | 3.84% | 3.84% | Y | 11.43 | 11.43 | |
| 8 | DAPAGZA M 5/1000 MG TABLET 10 | DAPAGZA M | EMCURE PHARMACEUTICALS LTD | 5/1000 MG | 10 | TABLET | 57.14 | 211075.16 | 0.56% | 0.56% | N | 5.71 | | |
| 9 | GLUXIT M FORTE 5/1000 MG TABLET 10 | GLUXIT M | ERIS LIFESCIENCES LTD | 5/1000 MG | 10 | TABLET | 59.3 | 1948352.44 | 5.14% | 5.14% | Y | 5.93 | 5.93 | |
| 10 | DAPARYL M 5/1000 MG TABLET 10 | DAPARYL M | INTAS PHARMACEUTICALS LTD | 5/1000 MG | 10 | TABLET | 71.07 | 2868785.05 | 7.56% | 7.56% | Y | 7.11 | 7.11 | |
| 11 | DAPAVEL M 5/1000 MG TABLET 10 | DAPAVEL M | INTAS PHARMACEUTICALS LTD | 5/1000 MG | 10 | TABLET | 71.07 | 3431541.57 | 9.05% | 9.05% | Y | 7.11 | 7.11 | |
| 12 | DAPACOSE M FORTE 5/1000 MG TABLET 10 | DAPACOSE M | JB CHEMICALS | 5/1000 MG | 10 | TABLET | 60.32 | 784944.16 | 2.07% | 2.07% | Y | 6.03 | 6.03 | |
| 13 | DAPAHENZ M 5/1000 MG TABLET 10 | DAPAHENZ M | LA RENON | 5/1000 MG | 10 | TABLET | 92.14 | 30774.76 | 0.08% | 0.08% | N | 9.21 | | |
| 14 | DAPATURN M FORTE 5/1000 MG TABLET 10 | DAPATURN M | LUPIN LTD | 5/1000 MG | 10 | TABLET | 60.31 | 1368494.21 | 3.61% | 3.61% | Y | 6.03 | 6.03 | |
| 15 | DAMITA M 5/1000 MG TABLET 10 | DAMITA M | MACLEODS PHARMACEUTICALS PVT.LTD | 5/1000 MG | 10 | TABLET | 64.93 | 180700.19 | 0.48% | 4.99% | Y | 6.49 | 6.49 | |
| 16 | DAMITA M 5/1000 MG TABLET 15 | DAMITA M | MACLEODS PHARMACEUTICALS PVT.LTD | 5/1000 MG | 15 | TABLET | 97.39 | 1709486.67 | 4.51% | 4.99% | Y | 6.49 | 6.49 | |
| 17 | DAPAMAC M 5/1000 MG TABLET 10 | DAPAMAC M | MACLEODS PHARMACEUTICALS PVT.LTD | 5/1000 MG | 10 | TABLET | 64.93 | 249201.34 | 0.66% | 8.74% | Y | 6.49 | 6.49 | |
| 18 | DAPAMAC M 5/1000 MG TABLET 15 | DAPAMAC M | MACLEODS PHARMACEUTICALS PVT.LTD | 5/1000 MG | 15 | TABLET | 97.39 | 2305903.03 | 6.09% | 8.74% | Y | 6.49 | 6.49 | |
| 19 | JUSTOZA M 5/1000 MG TABLET 10 | JUSTOZA M | MANKIND PHARMACEUTICALS LTD. | 5/1000 MG | 10 | TABLET | 60.31 | 1671551.96 | 4.41% | 4.41% | Y | 6.03 | 6.03 | |
| 20 | SGLTO M 5/1000 MG TABLET 10 | SGLTO M | MANKIND PHARMACEUTICALS LTD. | 5/1000 MG | 10 | TABLET | 60.31 | 59224.42 | 0.16% | 0.16% | N | 6.03 | | |
| 21 | DAPABLIS M 5/1000 MG TABLET 10 | DAPABLIS M | MED MANOR ORGANICS PVT LTD. | 5/1000 MG | 10 | TABLET | 66.43 | 14793.24 | 0.04% | 0.04% | N | 6.64 | | |
| 22 | DAPANOVA M 5/1000 MG TABLET 15 | DAPANOVA M | MEDLEY PHARMACEUTICALS | 5/1000 MG | 15 | TABLET | 181.07 | 3061413.57 | 8.07% | 8.07% | Y | 12.07 | 12.07 | |
| 23 | DAPAONE M 5/1000 MG TABLET 10 | DAPAONE M | MSN LABORATORIES LTD | 5/1000 MG | 10 | TABLET | 65 | 373490.00 | 0.98% | 0.98% | N | 6.50 | | |
| 24 | DAPABEST M 5/1000 MG TABLET 10 | DAPABEST M | PANACEA BIOTEC LTD | 5/1000 MG | 10 | TABLET | 58.8 | 49156.80 | 0.13% | 0.13% | N | 5.88 | | |
| 25 | GLIFOPRIME M 5/1000 MG TABLET 15 | GLIFOPRIME M | PRIMUS REMEDIES PVT LTD | 5/1000 MG | 15 | TABLET | 90.48 | 20629.44 | 0.05% | 0.05% | N | 6.03 | | |
| 26 | DPO M 5/1000 MG TABLET 10 | DPO M | RPG LIFE SCIENCES LTD. | 5/1000 MG | 10 | TABLET | 89.29 | 115987.71 | 0.31% | 0.31% | N | 8.93 | | |
| 27 | MDAPA 5 M FORTE 5/1000 MG TABLET 10 | MDAPA 5 M FORTE | SINSAN PHARMACEUTICALS | 5/1000 MG | 10 | TABLET | 100 | 3500.00 | 0.01% | 0.01% | N | 10.00 | | |
| 28 | DAPASPEC M TABLET 10 | DAPASPEC M | SPECTRA THERAPEUTICS PVT. LTD. | 5/1000 MG | 10 | TABLET | 79.65 | 1327685.85 | 3.50% | 3.50% | Y | 7.97 | 7.97 | |
| 29 | DAPEFY M 5/1000 MG TABLET IR 14 | DAPEFY M | SUN PHARMA LABORATORIES LTD. | 5/1000 MG | 14 | TABLET IR | 145 | | | | | | | |
| 30 | OKXRAMET 5/1000 MG TABLET 14 | OKXRAMET | SUN PHARMA LABORATORIES LTD. | 5/1000 MG | 14 | TABLET | 145 | | | | | | | |

434

| | | | | | | | | | | | | | | |
|----|----------------------------------|----------------|------------------------------|-----------|----|-----------|-------|------------|--------|--------|---|------|------|--|
| 31 | OXRAMET IR 5/1000 MG TABLET 14 | OXRAMET IR | SUN PHARMA LABORATORIES LTD. | 5/1000 MG | 14 | TABLET | 145 | | | | | | | |
| 32 | GLUCRETA M 5/1000 MG TABLET 10 | GLUCRETA M | TORRENT PHARMACEUTICALS LTD. | 5/1000 MG | 10 | TABLET | 73.39 | 5898237.61 | 15.55% | 15.55% | Y | 7.34 | 7.34 | |
| 33 | UDAPA M 5/1000 MG TABLET XR 10 | UDAPA M | USV PVT LTD | 5/1000 MG | 10 | TABLET XR | 58.32 | 939593.52 | 2.48% | 2.48% | Y | 5.83 | 5.83 | |
| 34 | DIUTEN M 5/1000 MG TABLET 15 | DIUTEN M | WOCKHARDT LTD | 5/1000 MG | 15 | TABLET | 96.48 | 19103.04 | 0.05% | 0.05% | N | 6.43 | | |
| 35 | ZINODAP M 5/1000 MG TABLET SR 15 | ZINODAP M | WOCKHARDT LTD | 5/1000 MG | 15 | TABLET SR | 96.48 | 491083.20 | 1.29% | 1.29% | Y | 6.43 | 6.43 | |
| | | Rs. Per Tablet | | | | | | | | | | | | |
| | Worked out Retail Price | 8.24 | Excluding GST | | | | | | | | | | | |

435

| | | | | | | | | | | | | | |
|----|-------------------------------------|----------------|------------------------------------|------------|----|-----------|--------|-------------|--------|--------|---|-------|-------|
| 31 | SUITGLIP M 50/1000 MG TABLET XR 10 | SUITGLIP M | IPCA LABORATORIES PVT LTD. | 50/1000 MG | 10 | TABLET XR | 64.29 | 30912.52 | 0.03% | 0.07% | N | 6.43 | |
| 32 | SITACOSE M 50/1000 MG TABLET 10 | SITACOSE M | JB CHEMICALS | 50/1000 MG | 10 | TABLET | 100.01 | 45904.59 | 0.04% | 0.04% | N | 10.00 | |
| 33 | SITACOSE MSR 50/1000 MG TABLET 10 | SITACOSE MSR | JB CHEMICALS | 50/1000 MG | 10 | TABLET | 107.15 | 29787.70 | 0.02% | 0.02% | N | 10.72 | |
| 34 | SITAHENZ M 50/1000 MG TABLET 10 | SITAHENZ M | LA RENON | 50/1000 MG | 10 | TABLET | 105.71 | 2160078.14 | 1.78% | 1.78% | Y | 10.57 | 10.67 |
| 35 | SITAHENZ MQ 50/1000 MG TABLET 10 | SITAHENZ MQ | LA RENON | 50/1000 MG | 10 | TABLET | 158.57 | 130344.54 | 0.11% | 0.56% | N | 15.86 | |
| 36 | SITAHENZ MQ 50/1000 MG TABLET 15 | SITAHENZ MQ | LA RENON | 50/1000 MG | 15 | TABLET | 158.57 | 569742.01 | 0.47% | 0.56% | N | 10.57 | |
| 37 | SUGARAY M 50/1000 MG TABLET 15 | SUGARAY M | LLOYD HEALTHCARE PVT.LTD | 50/1000 MG | 15 | TABLET | 127.5 | 217770.00 | 0.18% | 0.34% | N | 8.50 | |
| 38 | SUGARAY M 50/1000 MG TABLET SR 15 | SUGARAY M | LLOYD HEALTHCARE PVT.LTD | 50/1000 MG | 15 | TABLET SR | 148.94 | 189451.68 | 0.16% | 0.34% | N | 9.93 | |
| 39 | LUPISIT M 50/1000 MG TABLET 10 | LUPISIT M | LUPIN LTD | 50/1000 MG | 10 | TABLET | 92.86 | 6779515.74 | 5.58% | 5.58% | Y | 9.29 | 9.29 |
| 40 | MACSITA M 50/1000 MG TABLET 10 | MACSITA M | MACLEODS PHARMACEUTICALS PVT.LTD | 50/1000 MG | 10 | TABLET | 82.14 | 1901623.14 | 1.57% | 2.31% | Y | 8.21 | 8.21 |
| 41 | MACSITA M 50/1000 MG TABLET XR 10 | MACSITA M | MACLEODS PHARMACEUTICALS PVT.LTD | 50/1000 MG | 10 | TABLET XR | 95 | 902310.00 | 0.74% | 2.31% | Y | 9.50 | 8.50 |
| 42 | SITA OD MET 50/1000 MG TABLET 10 | SITA OD MET | MACLEODS PHARMACEUTICALS PVT.LTD | 50/1000 MG | 10 | TABLET | 82.14 | 2748979.38 | 2.26% | 2.26% | Y | 8.21 | 8.21 |
| 43 | SITA OD MSR 50/1000 MG TABLET 10 | SITA OD MSR | MACLEODS PHARMACEUTICALS PVT.LTD | 50/1000 MG | 10 | TABLET | 95 | 612370.00 | 0.50% | 0.50% | N | 9.50 | |
| 44 | SITACCLASS 50/1000 MG TABLET 10 | SITACCLASS | MACLEODS PHARMACEUTICALS PVT.LTD | 50/1000 MG | 10 | TABLET | 75.71 | 3709.79 | 0.00% | 0.00% | N | 7.57 | |
| 45 | SITACCLASS M 50/1000 MG TABLET 10 | SITACCLASS M | MACLEODS PHARMACEUTICALS PVT.LTD | 50/1000 MG | 10 | TABLET | 82.14 | 430560.02 | 0.35% | 0.35% | N | 8.21 | |
| 46 | SITACCLASS MSR 50/1000 MG TABLET 10 | SITACCLASS MSR | MACLEODS PHARMACEUTICALS PVT.LTD | 50/1000 MG | 10 | TABLET | 95 | 72580.00 | 0.06% | 0.06% | N | 9.60 | |
| 47 | SITADAY M 50/1000 MG TABLET 15 | SITADAY M | MANKIND PHARMACEUTICALS LTD. | 50/1000 MG | 15 | TABLET | 116.79 | 2721790.95 | 2.24% | 2.24% | Y | 7.79 | 7.79 |
| 48 | CORSITA M 50/1000 MG TABLET 10 | CORSITA M | MEDLEY PHARMACEUTICALS | 50/1000 MG | 10 | TABLET | 92.14 | 832484.90 | 0.69% | 0.69% | N | 9.21 | |
| 49 | SITANORM M 50/1000 MG TABLET 15 | SITANORM M | MICRO LABS LTD | 50/1000 MG | 15 | TABLET | 117.14 | 1767408.32 | 1.45% | 1.45% | Y | 7.81 | 7.81 |
| 50 | SITAPRIDE M 50/1000 MG TABLET 15 | SITAPRIDE M | MICRO LABS LTD | 50/1000 MG | 15 | TABLET | 117.14 | 2284464.28 | 1.88% | 1.88% | Y | 7.81 | 7.81 |
| 51 | JANUMET 50/1000 MG TABLET 15 | JANUMET | MSD PHARMACEUTICALS PRIVATE LTD. | 50/1000 MG | 15 | TABLET | 248.22 | | | | | | |
| 52 | SITANAT M 50/1000 MG TABLET 10 | SITANAT M | NATCO PHARMA LTD | 50/1000 MG | 10 | TABLET | 111.75 | 1738893.00 | 1.43% | 1.43% | Y | 11.18 | 11.18 |
| 53 | GLIPCRIN M 50/1000 MG TABLET 15 | GLIPCRIN M | PRIMUS REMEDIES PVT LTD | 50/1000 MG | 15 | TABLET | 139.29 | 103074.60 | 0.08% | 0.08% | N | 9.29 | |
| 54 | ISTAMET 50/1000 MG TABLET 15 | ISTAMET | SUN PHARMA LABORATORIES LTD. | 50/1000 MG | 15 | TABLET | 112.5 | | | | | | |
| 55 | SITARED M 50/1000 MG TABLET 15 | SITARED M | SUN PHARMA LABORATORIES LTD. | 50/1000 MG | 15 | TABLET | 112.5 | | | | | | |
| 56 | SITALENT M 50/1000 MG TABLET SR 10 | SITALENT M | TALENT INDIA | 50/1000 MG | 10 | TABLET SR | 132.15 | 340947.00 | 0.28% | 0.28% | N | 13.22 | |
| 57 | ZYSITA M 50/1000 MG TABLET 15 | ZYSITA M | THREE DOTS LIFESCIENCE | 50/1000 MG | 15 | TABLET | 214.29 | 47143.80 | 0.04% | 0.04% | N | 14.29 | |
| 58 | SITAXA M 50/1000 MG TABLET 15 | SITAXA M | TORRENT PHARMACEUTICALS LTD. | 50/1000 MG | 15 | TABLET | 148.93 | 7471669.17 | 6.15% | 6.15% | Y | 9.93 | 9.93 |
| 59 | STALIX M 50/1000 MG TABLET 15 | STALIX M | TORRENT PHARMACEUTICALS LTD. | 50/1000 MG | 15 | TABLET | 148.93 | 22882647.71 | 18.83% | 18.83% | Y | 9.93 | 9.93 |
| 60 | SITAWOK M 50/1000 MG TABLET 15 | SITAWOK M | WOCKHARDT LTD | 50/1000 MG | 15 | TABLET | 107.04 | 3875704.32 | 3.18% | 3.18% | Y | 7.14 | 7.14 |
| 61 | SITASAR M 50/1000 MG TABLET 10 | SITASAR M | WONSET HEALTH CARE PRIVATE LIMITED | 50/1000 MG | 10 | TABLET | 67.86 | 27091.60 | 0.02% | 0.02% | N | 6.79 | |
| 62 | ZENSITA M 1000/50 MG TABLET 15 | ZENSITA M | ZUVENTUS HEALTHCARE LTD | 1000/50 MG | 15 | TABLET | 112.5 | 1190475.00 | 0.98% | 0.98% | N | 7.50 | |
| 63 | SIGLYN M 50/1000 MG TABLET 10 | SIGLYN M | ZYDUS CADILA - ZHL | 50/1000 MG | 10 | TABLET | 85.71 | 147935.46 | 0.12% | 2.22% | Y | 8.57 | 8.57 |
| 64 | SIGLYN M 50/1000 MG TABLET ER 10 | SIGLYN M | ZYDUS CADILA - ZHL | 50/1000 MG | 10 | TABLET ER | 85.71 | 2059354.17 | 1.69% | 2.22% | Y | 8.57 | 8.57 |
| 65 | SIGLYN M 50/1000 MG TABLET IR 10 | SIGLYN M | ZYDUS CADILA - ZHL | 50/1000 MG | 10 | TABLET IR | 82.14 | 504175.32 | 0.41% | 2.22% | Y | 8.21 | 8.21 |
| 66 | SITAGLYN M 50/1000 MG TABLET 10 | SITAGLYN M | ZYDUS CADILA - ZHL | 50/1000 MG | 10 | TABLET | 85.71 | 2377938.24 | 1.96% | 2.63% | Y | 8.57 | 8.57 |
| 67 | SITAGLYN M 50/1000 MG TABLET IR 10 | SITAGLYN M | ZYDUS CADILA - ZHL | 50/1000 MG | 10 | TABLET IR | 82.14 | 818114.40 | 0.67% | 2.63% | Y | 8.21 | 8.21 |
| | | Rs. Per Tablet | | | | | | | | | | | |
| | Worked out Retail Price | 10.37 | Excluding GST | | | | | | | | | | |

437

Computation of Retail Price based on January, 2023 Data under Para 5 of DPCO, 2013

Subject: Retail price fixation under Para 5 of DPCO, 2013 – Each film coated bilayered tablet contains: Dapagliflozin + Metformin

| | | | | | |
|--|--|--|--|--|----------|
| Number of Companies consisting of Market Share of 1% & Above | | | | | 13 |
| Sum of MAT value considered for price calculation (in Lakhs) | | | | | 1,433.88 |
| Sum of PTR per unit considered for price calculation | | | | | 96.37 |
| Number of Packs considered | | | | | 16 |
| Average PTR | | | | | 6.02 |
| Add : 16% Retailer Margin | | | | | 0.96 |
| Retail Price (without local taxes) | | | | | 6.98 |
| % Reduction with compared to Highest Price | | | | | 45.27% |

| | | | |
|---------------------------------|--|--|-------|
| Minimum Price (Rs.) | | | 4.93 |
| Maximum Price (Rs.) | | | 11.00 |
| Average of all considered (Rs.) | | | 6.02 |
| Retail Price (Rs.) | | | 6.98 |

| S.No. | पैक विवरण Pack Description | ब्रांड BRAND | कंपनी Company | Strength | Pack Size | Unit | TOTAL MAT | 14,57,38,547 | 100% | M3 | | | Price per Unit (Rs.) | Price per Unit (Rs.) Considered |
|-------|---------------------------------|-----------------|----------------------------------|----------|-----------|-----------|-----------|--------------|-------------------|--|--------------------------------|-------|-------------------------|---------------------------------------|
| | | | | | | | PTR(Rs.) | MAT(Rs.) | SKU wise MAT % | Brandwise MAT (ignoring 0% MAT) | Quality (Y/N) Y=Yes N=No | | | |
| 1 | DAPANTA M 5/500 MG TABLET 10 | DAPANTA M | AJANTA PHARMA LTD | 5/500 MG | 10 | TABLET | 38.4 | 23462.40 | 0.02% | 0.02% | N | 3.84 | | |
| 2 | DAPANORM M 5/500 MG TABLET 10 | DAPANORM M | ALKEM LABORATORIES LTD. | 5/500 MG | 10 | TABLET | 59.29 | 18229797.89 | 12.51% | 12.51% | Y | 5.93 | 5.93 | |
| 3 | DAPRICA M 5/500 MG TABLET 10 | DAPRICA M | APRICA HEALTHCARE PVT LTD | 5/500 MG | 10 | TABLET | 60.17 | 655387.44 | 0.45% | 0.45% | N | 6.02 | | |
| 4 | DAPABITE M 5/500 MG TABLET 10 | DAPABITE M | CORONA | 5/500 MG | 10 | TABLET | 61.32 | 4880198.08 | 3.35% | 3.35% | Y | 6.13 | 6.13 | |
| 5 | DAPLO M 5/500 MG TABLET 10 | DAPLO M | DR. REDDYS LABORATORIES LTD | 5/500 MG | 10 | TABLET | 110 | 10253360.00 | 7.04% | 7.04% | Y | 11.00 | 11.00 | |
| 6 | DAPAZEP M 5/500 MG TABLET 10 | DAPAZEP M | ERGOS LIFE SCIENCES | 5/500 MG | 10 | TABLET | 50 | 3050.00 | 0.00% | 0.00% | N | 5.00 | | |
| 7 | GLUXIT M 5/500 MG TABLET 10 | GLUXIT M | ERIS LIFESCIENCES LTD | 5/500 MG | 10 | TABLET | 59.3 | 13426567.08 | 9.21% | 8.21% | Y | 5.93 | 5.93 | |
| 8 | DEXIGLU M 5/500 MG TABLET 10 | DEXIGLU M | FUSION HEALTHCARE PVT LTD | 5/500 MG | 10 | TABLET | 49.79 | 3001247.40 | 2.06% | 2.06% | Y | 4.98 | 4.98 | |
| 9 | DAPARYL M 5/500 MG TABLET 10 | DAPARYL M | INTAS PHARMACEUTICALS LTD | 5/500 MG | 10 | TABLET | 58.93 | 14138981.42 | 9.70% | 9.70% | Y | 5.89 | 5.89 | |
| 10 | DAPAVEL M 5/500 MG TABLET 10 | DAPAVEL M | INTAS PHARMACEUTICALS LTD | 5/500 MG | 10 | TABLET | 58.93 | 14650369.13 | 10.05% | 10.05% | Y | 5.89 | 5.89 | |
| 11 | DMBEST M 5/500 MG TABLET 10 | DMBEST M | KEPLER HEALTH CARE | 5/500 MG | 10 | TABLET | 50.71 | 56896.62 | 0.04% | 0.04% | N | 5.07 | | |
| 12 | DAPATURN M 5/500 MG TABLET 10 | DAPATURN M | LUPIN LTD | 5/500 MG | 10 | TABLET | 50 | 3612700.00 | 2.48% | 2.48% | Y | 5.00 | 5.00 | |
| 13 | DAMITA M 5/500 MG TABLET 10 | DAMITA M | MACLEODS PHARMACEUTICALS PVT.LTD | 5/500 MG | 10 | TABLET | 50.88 | 8150023.10 | 5.59% | 5.59% | Y | 5.09 | 5.09 | |
| 14 | DAPAMAC M 5/500 MG TABLET 10 | DAPAMAC M | MACLEODS PHARMACEUTICALS PVT.LTD | 5/500 MG | 10 | TABLET | 53.86 | 10077583.02 | 6.91% | 6.91% | Y | 5.38 | 5.38 | |
| 15 | DAPAMAC M 5/500 MG TABLET 15 | DAPAMAC M | MACLEODS PHARMACEUTICALS PVT.LTD | 5/500 MG | 15 | TABLET | 76.31 | 2852011.86 | 1.96% | 8.87% | Y | 6.09 | 5.09 | |
| 16 | JUSTOZA M 5/500 MG TABLET 10 | JUSTOZA M | MANKIND PHARMACEUTICALS LTD. | 5/500 MG | 10 | TABLET | 50 | 7030600.00 | 4.82% | 4.82% | Y | 5.00 | 5.00 | |
| 17 | SGLTD M 5/500 MG TABLET 10 | SGLTD M | MANKIND PHARMACEUTICALS LTD. | 5/500 MG | 10 | TABLET | 50 | 267600.00 | 0.18% | 0.18% | N | 5.00 | | |
| 18 | DAPABLIS M 5/500 MG TABLET 10 | DAPABLIS M | MED MANOR ORGANICS PVT LTD. | 5/500 MG | 10 | TABLET | 55.71 | 28523.52 | 0.02% | 0.02% | N | 5.57 | | |
| 19 | DAPANOVA M 5/500 MG TABLET 15 | DAPANOVA M | MEDLEY PHARMACEUTICALS | 5/500 MG | 15 | TABLET | 127.5 | 12441832.50 | 8.54% | 8.54% | Y | 8.50 | 8.50 | |
| 20 | DAPADNE M 5/500 MG TABLET 10 | DAPADNE M | MSN LABORATORIES LTD | 5/500 MG | 10 | TABLET | 55 | 1475320.00 | 1.01% | 1.01% | Y | 5.50 | 5.50 | |
| 21 | GLUFOPRIME M 5/500 MG TABLET 15 | GLUFOPRIME M | PRIMUS REMEDIES PVT LTD | 5/500 MG | 15 | TABLET | 75 | 63075.00 | 0.04% | 0.04% | N | 5.00 | | |
| 22 | MDAPA 10 M 5/500 MG TABLET 10 | MDAPA 10 M | SINSAN PHARMACEUTICALS | 5/500 MG | 10 | TABLET | 123.21 | 884278.17 | 0.61% | 0.61% | N | 12.32 | | |
| 23 | MDAPA 5 M 5/500 MG TABLET 10 | MDAPA 5 M | SINSAN PHARMACEUTICALS | 5/500 MG | 10 | TABLET | 75 | 202276.01 | 0.14% | 0.14% | N | 7.50 | | |
| 24 | SINXIGA 5 M 5/500 MG TABLET 10 | SINXIGA 5 M | SINSAN PHARMACEUTICALS | 5/500 MG | 10 | TABLET | 75 | 23700.00 | 0.02% | 0.02% | N | 7.50 | | |
| 25 | SINXIGA M 5/500 MG TABLET 10 | SINXIGA M | SINSAN PHARMACEUTICALS | 5/500 MG | 10 | TABLET | 123.21 | 79841.80 | 0.05% | 0.05% | N | 12.32 | | |
| 26 | DAPEFY M 5/500 MG TABLET IR 14 | DAPEFY M | SUN PHARMA LABORATORIES LTD. | 5/500 MG | 14 | TABLET IR | 70 | | | | | | | |
| 27 | OXRAMET 5/500 MG TABLET 14 | OXRAMET | SUN PHARMA LABORATORIES LTD. | 5/500 MG | 14 | TABLET | 70 | | | | | | | |
| 28 | OXRAMET IR 5/500 MG TABLET 14 | OXRAMET IR | SUN PHARMA LABORATORIES LTD. | 5/500 MG | 14 | TABLET | 70 | | | | | | | |
| 29 | DAPIXA M 5/500 MG TABLET 10 | DAPIXA M | TAS MED (INDIA) PRIVATE LTD. | 5/500 MG | 10 | TABLET | 77.14 | 62792.80 | 0.04% | 0.04% | N | 7.71 | | |
| 30 | GLUCRETA M 5/500 MG TABLET 10 | GLUCRETA M | TORRENT PHARMACEUTICALS LTD. | 5/500 MG | 10 | TABLET | 61.21 | 14974082.93 | 10.27% | 10.27% | Y | 6.12 | 6.12 | |

450

| | | | | | | | | | | | | | |
|----|-------------------------------|----------------|---------------|----------|----|-----------|-------|------------|-------|-------|---|------|------|
| 31 | UDAPA M 5/500 MG TABLET XR 10 | UDAPA M | USV PVT LTD | 5/500 MG | 10 | TABLET XR | 49.28 | 4192588.80 | 2.88% | 2.88% | Y | 4.93 | 4.93 |
| | | Rs. Per Tablet | | | | | | | | | | | |
| | Worked out Retail Price | 6.98 | Excluding GST | | | | | | | | | | |

Computation of Retail Price based on January, 2023 Data under Para 5 of DPCO, 2013

Subject: Retail price fixation under Para 5 of DPCO, 2013 – Each film coated bilayered tablet contains: Sitagliptin + Metformin

| | | | | | |
|--|--|--|--|--|----------|
| Number of Companies consisting of Market Share of 1% & Above | | | | | 21 |
| Sum of MAT value considered for price calculation (in Lakhs) | | | | | 3,972.33 |
| Sum of PTR per unit considered for price calculation | | | | | 292.48 |
| Number of Packs considered | | | | | 37 |
| Average PTR | | | | | 7.90 |
| Add: 16% Retailer Margin | | | | | 1.26 |
| Retail Price (without local taxes) | | | | | 9.16 |
| % Reduction with compared to Highest Price | | | | | 29.34% |

| | | |
|---------------------------------|--|-------|
| Minimum Price (Rs.) | | 5.19 |
| Maximum Price (Rs.) | | 11.18 |
| Average of all considered (Rs.) | | 7.90 |
| Retail Price (Rs.) | | 9.16 |

| S.No. | पैक विवरण Pack Description | छाप BRAND | कंपनी Company | Strength | Pack Size | Unit | TOTAL MAT | 42,69,51,197 | 100% | M3 | | | |
|-------|----------------------------------|--------------|--|-----------|-----------|-----------|-----------|--------------|-------------------|--|--------------------------------|-------------------------|---------------------------------------|
| | | | | | | | PTR(Rs.) | MAT(Rs.) | SKU wise MAT % | Brandwise MAT (ignoring O% MAT) | Quality (Y/N) Y=Yes N=No | Price per Unit (Rs.) | Price per Unit (Rs.) Considered |
| 1 | SIAGLUDE M 50/500 MG TABLET 15 | SIAGLUDE M | ABBOTT HEALTHCARE PVT. LTD | 50/500 MG | 15 | TABLET | 155.36 | 9556970.40 | 2.24% | 2.24% | Y | 10.36 | 10.36 |
| 2 | ACSITA M 50/500 MG TABLET 15 | ACSITA M | ACMEDIX PHARMA LLP | 50/500 MG | 15 | TABLET | 63.57 | 140743.98 | 0.03% | 0.03% | N | 4.24 | |
| 3 | SITAMAX M 50/500 MG TABLET 10 | SITAMAX M | AJANTA PHARMA LTD | 50/500 MG | 10 | TABLET | 67.86 | 1897026.12 | 0.44% | 0.44% | N | 6.79 | |
| 4 | SITAPAZ M 50/500 MG TABLET 10 | SITAPAZ M | AKESISS PHARMA (P) LTD | 50/500 MG | 10 | TABLET | 85 | 1357025.00 | 0.32% | 0.32% | N | 8.50 | |
| 5 | SITALEMBIC M 50/500 MG TABLET 15 | SITALEMBIC M | ALEMBIC LTD | 50/500 MG | 15 | TABLET | 107.14 | 8711017.70 | 2.04% | 2.04% | Y | 7.14 | 7.14 |
| 6 | ALSITA M 50/500 MG TABLET 10 | ALSITA M | ALKEM LABORATORIES LTD. | 50/500 MG | 10 | TABLET | 63.57 | 19612616.40 | 4.59% | 5.15% | Y | 6.36 | 6.36 |
| 7 | ALSITA M 50/500 MG TABLET IR 10 | ALSITA M | ALKEM LABORATORIES LTD. | 50/500 MG | 10 | TABLET IR | 56.43 | 2387101.86 | 0.56% | 5.15% | Y | 5.64 | 5.64 |
| 8 | SITALONG M 50/500 MG TABLET 15 | SITALONG M | ALTEUS BIOGENICS PVT.LTD. | 50/500 MG | 15 | TABLET | 150 | 144000.00 | 0.03% | 0.03% | N | 10.00 | |
| 9 | SITAGLIP M 500/50 MG TABLET 10 | SITAGLIP M | ANTHEM BIOPHARMA PVT LTD | 500/50 MG | 10 | TABLET | 96.43 | 602783.93 | 0.14% | 0.14% | N | 9.64 | |
| 10 | SIDIAMET 50/500 MG TABLET 10 | SIDIAMET | APRICA HEALTHCARE PVT LTD | 50/500 MG | 10 | TABLET | 128.57 | 58370.78 | 0.01% | 0.20% | N | 12.86 | |
| 11 | SIDIAMET 50/500 MG TABLET 15 | SIDIAMET | APRICA HEALTHCARE PVT LTD | 50/500 MG | 15 | TABLET | 128.57 | 551051.02 | 0.13% | 0.20% | N | 8.57 | |
| 12 | SIDIAMET 50/500 MG TABLET XR 15 | SIDIAMET | APRICA HEALTHCARE PVT LTD | 50/500 MG | 15 | TABLET XR | 128.57 | 254825.74 | 0.06% | 0.20% | N | 6.57 | |
| 13 | SITAGLO M 50/500 MG TABLET 15 | SITAGLO M | ARISTO PHARMACEUTICALS PVT. LTD | 50/500 MG | 15 | TABLET | 117.86 | 13442758.02 | 3.15% | 3.15% | Y | 7.86 | 7.86 |
| 14 | TERGRA M 50/500 MG TABLET 10 | TERGRA M | BIOCON LTD | 50/500 MG | 10 | TABLET | 89.29 | 1293365.65 | 0.30% | 0.30% | N | 8.93 | |
| 15 | JANKEY M 50/500 MG TABLET 15 | JANKEY M | CADILA PHARMACEUTICALS LTD | 50/500 MG | 15 | TABLET | 116.79 | 1346121.54 | 0.32% | 0.32% | N | 7.79 | |
| 16 | SITENALI M 50/500 MG TABLET 15 | SITENALI M | CADILA PHARMACEUTICALS LTD | 50/500 MG | 15 | TABLET | 116.79 | 1189973.31 | 0.28% | 0.28% | N | 7.79 | |
| 17 | SITACIP M 50/500 MG TABLET 10 | SITACIP M | CIPLA LTD. | 50/500 MG | 10 | TABLET | 77.86 | 14810613.89 | 3.47% | 3.47% | Y | 7.79 | 7.79 |
| 18 | SITABITE M 50/500 MG TABLET 10 | SITABITE M | CORONA | 50/500 MG | 10 | TABLET | 77.86 | 18184981.60 | 4.28% | 4.33% | Y | 7.79 | 7.79 |
| 19 | SITABITE M 50/500 MG TABLET 15 | SITABITE M | CORONA | 50/500 MG | 15 | TABLET | 77.86 | 284734.02 | 0.07% | 4.33% | Y | 5.19 | 5.19 |
| 20 | STIG MT 50/500 MG TABLET 15 | STIG MT | DR. REDDYS LABORATORIES LTD | 50/500 MG | 15 | TABLET | 96.43 | 6743735.62 | 1.58% | 1.58% | Y | 6.43 | 6.43 |
| 21 | SITADYL M 50/500 MG TABLET 10 | SITADYL M | EUNOR PHARMA | 50/500 MG | 10 | TABLET | 114.29 | 49001.80 | 0.01% | 0.01% | N | 11.43 | |
| 22 | EMSITA M 50/500 MG TABLET 10 | EMSITA M | EMCURE PHARMACEUTICALS LTD | 50/500 MG | 10 | TABLET | 107.07 | 10484829.75 | 2.46% | 2.46% | Y | 10.71 | 10.71 |
| 23 | GLURA M 50/500 MG TABLET 15 | GLURA M | ERIS LIFESCIENCES LTD | 50/500 MG | 15 | TABLET | 128.57 | 5934534.06 | 1.39% | 5.80% | Y | 8.57 | 8.57 |
| 24 | GLURA M 50/500 MG TABLET XR 15 | GLURA M | ERIS LIFESCIENCES LTD | 50/500 MG | 15 | TABLET XR | 128.57 | 18808633.87 | 4.41% | 5.80% | Y | 8.57 | 8.57 |
| 25 | SITDC M 500/50 MG TABLET 15 | SITDC M | FDC LTD. | 500/50 MG | 15 | TABLET | 85 | 977160.00 | 0.23% | 0.23% | N | 5.67 | |
| 26 | CTASORIN M 50/500 MG TABLET 10 | CTASORIN M | FUSION HEALTHCARE PVT LTD | 50/500 MG | 10 | TABLET | 100 | 2021800.00 | 0.47% | 0.47% | N | 10.00 | |
| 27 | SITAZIT M 50/500 MG TABLET 10 | SITAZIT M | GLEN MARK PHARMACEUTICALS LTD. | 50/500 MG | 10 | TABLET | 89.29 | 14381672.43 | 3.37% | 3.37% | Y | 8.93 | 8.93 |
| 28 | QSITA M 50/500 MG TABLET 10 | QSITA M | HBC LIFESCIENCES PVT LTD | 50/500 MG | 10 | TABLET | 64.29 | 2009255.37 | 0.47% | 0.47% | N | 6.43 | |
| 29 | SPIKERID M 50/500 MG TABLET 10 | SPIKERID M | INDICHEMIE HEALTH SPECIALITIES PVT. LTD. | 50/500 MG | 10 | TABLET | 63.57 | 44499.00 | 0.01% | 0.01% | N | 6.36 | |
| 30 | IGNALIS M 50/500 MG TABLET 10 | IGNALIS M | INTAS PHARMACEUTICALS LTD | 50/500 MG | 10 | TABLET | 70.71 | 17154882.39 | 4.02% | 4.58% | Y | 7.07 | 7.07 |

| | | | | | | | | | | | | | |
|----|------------------------------------|----------------|------------------------------------|-----------|----|-----------|--------|-------------|-------|-------|---|-------|-------|
| 31 | IGNALIS M 50/500 MG TABLET IR 10 | IGNALIS M | INTAS PHARMACEUTICALS LTD | 50/500 MG | 10 | TABLET IR | 67.86 | 2398036.68 | 0.58% | 4.58% | Y | 6.78 | 6.78 |
| 32 | SITARA-M 50/500 MG TABLET 10 | SITARA-M | INTAS PHARMACEUTICALS LTD | 50/500 MG | 10 | TABLET | 70.71 | 12007689.36 | 2.81% | 6.69% | Y | 7.07 | 7.07 |
| 33 | SITARA-M 50/500 MG TABLET IR 10 | SITARA-M | INTAS PHARMACEUTICALS LTD | 50/500 MG | 10 | TABLET IR | 70.71 | 16562332.59 | 3.88% | 6.69% | Y | 7.07 | 7.07 |
| 34 | SUITGLIP M 50/500 MG TABLET 10 | SUITGLIP M | IPCA LABORATORIES PVT LTD. | 50/500 MG | 20 | TABLET | 64.29 | 368960.31 | 0.09% | 0.12% | N | 6.43 | |
| 35 | SUITGLIP M 50/500 MG TABLET XR 10 | SUITGLIP M | IPCA LABORATORIES PVT LTD. | 50/500 MG | 10 | TABLET XR | 64.29 | 111414.57 | 0.03% | 0.12% | N | 6.43 | |
| 36 | SITACOSE M 50/500 MG TABLET 10 | SITACOSE M | JB CHEMICALS | 50/500 MG | 10 | TABLET | 78.58 | 213166.12 | 0.05% | 0.05% | N | 7.88 | |
| 37 | SITAHENZ M 50/500 MG TABLET 10 | SITAHENZ M | LA RENON | 50/500 MG | 10 | TABLET | 91.43 | 17427472.30 | 4.08% | 4.08% | Y | 9.14 | 9.14 |
| 38 | SITAHENZ MQ 50/500 MG TABLET 10 | SITAHENZ MQ | LA RENON | 50/500 MG | 10 | TABLET | 137.14 | 523051.96 | 0.12% | 0.34% | N | 13.71 | |
| 39 | SITAHENZ MQ 50/500 MG TABLET 15 | SITAHENZ MQ | LA RENON | 50/500 MG | 15 | TABLET | 137.14 | 940506.12 | 0.22% | 0.34% | N | 9.14 | |
| 40 | SUGARAY M 50/500 MG TABLET 15 | SUGARAY M | LLOYD HEALTHCARE PVT.LTD | 50/500 MG | 15 | TABLET | 106.08 | 2525340.48 | 0.59% | 0.69% | N | 7.07 | |
| 41 | SUGARAY M 50/500 MG TABLET SR 15 | SUGARAY M | LLOYD HEALTHCARE PVT.LTD | 50/500 MG | 15 | TABLET SR | 138.22 | 424888.28 | 0.10% | 0.69% | N | 9.21 | |
| 42 | LUPISIT M 50/500 MG TABLET 10 | LUPISIT M | LUPIN LTD | 50/500 MG | 10 | TABLET | 85.71 | 27645931.91 | 6.48% | 8.48% | Y | 8.57 | 8.57 |
| 43 | MACSITA M 50/500 MG TABLET 10 | MACSITA M | MACLEODS PHARMACEUTICALS PVT.LTD | 50/500 MG | 10 | TABLET | 75.71 | 11321446.27 | 2.65% | 3.17% | Y | 7.57 | 7.57 |
| 44 | MACSITA M 50/500 MG TABLET XR 10 | MACSITA M | MACLEODS PHARMACEUTICALS PVT.LTD | 50/500 MG | 10 | TABLET XR | 82.14 | 2206280.40 | 0.52% | 3.17% | Y | 8.21 | 8.21 |
| 45 | SITA OD MET 50/500 MG TABLET 10 | SITA OD MET | MACLEODS PHARMACEUTICALS PVT.LTD | 50/500 MG | 10 | TABLET | 75.71 | 10329266.72 | 2.42% | 2.42% | Y | 7.57 | 7.57 |
| 46 | SITA OD MSR 50/500 MG TABLET 10 | SITA OD MSR | MACLEODS PHARMACEUTICALS PVT.LTD | 50/500 MG | 10 | TABLET | 82.14 | 1543985.58 | 0.36% | 0.36% | N | 8.21 | |
| 47 | SITACCLASS M 50/500 MG TABLET 10 | SITACCLASS M | MACLEODS PHARMACEUTICALS PVT.LTD | 50/500 MG | 10 | TABLET | 75.71 | 1820598.37 | 0.43% | 0.43% | N | 7.57 | |
| 48 | SITACCLASS MSR 50/500 MG TABLET 10 | SITACCLASS MSR | MACLEODS PHARMACEUTICALS PVT.LTD | 50/500 MG | 10 | TABLET | 82.14 | 168633.42 | 0.04% | 0.04% | N | 8.21 | |
| 49 | SITADAY M 50/500 MG TABLET 15 | SITADAY M | MANKIND PHARMACEUTICALS LTD. | 50/500 MG | 15 | TABLET | 106.07 | 12210884.47 | 2.86% | 2.86% | Y | 7.07 | 7.07 |
| 50 | CORSITA M 50/500 MG TABLET 10 | CORSITA M | MEDLEY PHARMACEUTICALS | 50/500 MG | 10 | TABLET | 77.86 | 4841957.68 | 1.13% | 1.13% | Y | 7.79 | 7.79 |
| 51 | JOSSITA M 50/500 MG TABLET 10 | JOSSITA M | MEDOPHARM | 50/500 MG | 10 | TABLET | 82.14 | 27024.06 | 0.01% | 0.01% | N | 8.21 | |
| 52 | SITANORM M 50/500 MG TABLET 15 | SITANORM M | MICRO LABS LTD | 50/500 MG | 15 | TABLET | 106.43 | 8983969.16 | 2.10% | 2.10% | Y | 7.10 | 7.10 |
| 53 | SITAPRIDE M 50/500 MG TABLET 15 | SITAPRIDE M | MICRO LABS LTD | 50/500 MG | 15 | TABLET | 106.43 | 12770322.84 | 2.99% | 2.99% | Y | 7.10 | 7.10 |
| 54 | JANUMET 50/500 MG TABLET 15 | JANUMET | MSD PHARMACEUTICALS PRIVATE LTD. | 50/500 MG | 15 | TABLET | 246.43 | | | | | | |
| 55 | SITA M 50/500 MG TABLET 10 | SITA M | MSN LABORATORIES LTD | 50/500 MG | 10 | TABLET | 74.29 | 174284.34 | 0.04% | 0.04% | N | 7.43 | |
| 56 | SITANAT M 50/500 MG TABLET 10 | SITANAT M | NATCO PHARMA LTD | 50/500 MG | 10 | TABLET | 111.75 | 4297569.75 | 1.01% | 1.01% | Y | 11.18 | 11.18 |
| 57 | GLIPCRIN M 50/500 MG TABLET 15 | GLIPCRIN M | PRIMUS REMEDIES PVT LTD | 50/500 MG | 15 | TABLET | 128.57 | 1919807.24 | 0.45% | 0.45% | N | 8.57 | |
| 58 | 6F1C M 50/500 MG TABLET 15 | 6F1C M | SINSAN PHARMACEUTICALS | 50/500 MG | 15 | TABLET | 159.29 | 43486.17 | 0.01% | 0.01% | N | 10.62 | |
| 59 | ISTAMET 50/500 MG TABLET 15 | ISTAMET | SUN PHARMA LABORATORIES LTD. | 50/500 MG | 15 | TABLET | 101.79 | | | | | | |
| 60 | SITARED M 50/500 MG TABLET 15 | SITARED M | SUN PHARMA LABORATORIES LTD. | 50/500 MG | 15 | TABLET | 101.79 | | | | | | |
| 61 | SITASYS M 50/500 MG TABLET 10 | SITASYS M | SYSTOPIC LABORATORIES LTD-MEM | 50/500 MG | 10 | TABLET | 60.71 | 177151.78 | 0.04% | 0.04% | N | 6.07 | |
| 62 | SITALENT M 50/500 MG TABLET SR 15 | SITALENT M | TALENT INDIA | 50/500 MG | 15 | TABLET SR | 170.36 | 919432.92 | 0.22% | 0.22% | N | 11.36 | |
| 63 | ZYSITA M 50/500 MG TABLET 15 | ZYSITA M | THREE DOTS LIFESCIENCE | 50/500 MG | 15 | TABLET | 187.5 | 88312.50 | 0.02% | 0.02% | N | 12.50 | |
| 64 | SITAXA M 50/500 MG TABLET 15 | SITAXA M | TORRENT PHARMACEUTICALS LTD. | 50/500 MG | 15 | TABLET | 138.21 | 28210734.15 | 8.61% | 7.17% | Y | 9.21 | 9.21 |
| 65 | SITAXA M 50/500 MG TABLET XR 10 | SITAXA M | TORRENT PHARMACEUTICALS LTD. | 50/500 MG | 10 | TABLET XR | 92.14 | 2373618.54 | 0.56% | 7.17% | Y | 9.21 | 9.21 |
| 66 | STALIX M 50/500 MG TABLET 15 | STALIX M | TORRENT PHARMACEUTICALS LTD. | 50/500 MG | 15 | TABLET | 138.21 | 24582307.02 | 5.76% | 6.35% | Y | 9.21 | 9.21 |
| 67 | STALIX M 50/500 MG TABLET XR 10 | STALIX M | TORRENT PHARMACEUTICALS LTD. | 50/500 MG | 10 | TABLET XR | 92.14 | 2501693.14 | 0.59% | 6.35% | Y | 9.21 | 9.21 |
| 68 | SITASON M 50/500 MG TABLET 10 | SITASON M | UNISON PHARMACEUTICALS | 50/500 MG | 10 | TABLET | 39.29 | 429046.80 | 0.10% | 0.10% | N | 3.93 | |
| 69 | SITAWOK M 50/500 MG TABLET 15 | SITAWOK M | WOCKHARDT LTD | 50/500 MG | 15 | TABLET | 96.32 | 8342949.44 | 1.95% | 1.95% | Y | 6.42 | 6.42 |
| 70 | SITASAR M 50/500 MG TABLET 10 | SITASAR M | WONSET HEALTH CARE PRIVATE LIMITED | 50/500 MG | 10 | TABLET | 67.86 | 59119.20 | 0.01% | 0.01% | N | 6.79 | |
| 71 | ZENSITA M 500/50 MG TABLET 15 | ZENSITA M | ZUVENTUS HEALTHCARE LTD | 500/50 MG | 15 | TABLET | 101.78 | 3313956.80 | 0.78% | 0.78% | N | 6.79 | |
| 72 | SIGLYN M 50/500 MG TABLET 10 | SIGLYN M | ZYDUS CADILA - ZHL | 50/500 MG | 10 | TABLET | 78.57 | 945039.96 | 0.22% | 3.89% | Y | 7.86 | 7.86 |
| 73 | SIGLYN M 50/500 MG TABLET ER 10 | SIGLYN M | ZYDUS CADILA - ZHL | 50/500 MG | 10 | TABLET ER | 78.57 | 13790056.41 | 3.23% | 3.89% | Y | 7.86 | 7.86 |
| 74 | SIGLYN M 50/500 MG TABLET IR 10 | SIGLYN M | ZYDUS CADILA - ZHL | 50/500 MG | 10 | TABLET IR | 75 | 1877025.00 | 0.44% | 3.89% | Y | 7.50 | 7.50 |
| 75 | SITAGLYN M 50/500 MG TABLET 10 | SITAGLYN M | ZYDUS CADILA - ZHL | 50/500 MG | 10 | TABLET | 78.57 | 10019010.69 | 2.35% | 2.60% | Y | 7.86 | 7.86 |
| 76 | SITAGLYN M 50/500 MG TABLET IR 10 | SITAGLYN M | ZYDUS CADILA - ZHL | 50/500 MG | 10 | TABLET IR | 75 | 1088250.00 | 0.25% | 2.60% | Y | 7.50 | 7.50 |
| | | Rs. Per Tablet | | | | | | | | | | | |
| | Worked out Retail Price | 9.16 | Excluding GST | | | | | | | | | | |

Computation of Retail Price based on January, 2023 Data under Para 5 of DPCO, 2013

Subject: Retail price fixation under Para 5 of DPCO, 2013 – Each film coated bilayered tablet contains: Dapagliflozin

| | | | | | |
|--|--|--|--|--|----------|
| Number of Companies consisting of Market Share of 1% & Above | | | | | 18 |
| Sum of MAT value considered for price calculation (in Lakhs) | | | | | 6,369.81 |
| Sum of PTR per unit considered for price calculation | | | | | 175.77 |
| Number of Packs considered | | | | | 23 |
| Average PTR | | | | | 7.64 |
| Add : 16% Retailer Margin | | | | | 1.22 |
| Retail Price (without local taxes) | | | | | 8.88 |
| % Reduction with compared to Highest Price | | | | | 30.55% |

| | | |
|---------------------------------|--|-------|
| Minimum Price (Rs.) | | 2.79 |
| Maximum Price (Rs.) | | 11.00 |
| Average of all considered (Rs.) | | 7.64 |
| Retail Price (Rs.) | | 8.86 |

| S.No. | पैक विवरण Pack Description | छाप BRAND | कंपनी Company | Strength | Pack Size | Unit | TOTAL MAT | 59,02,06,386 | 100% | Brandwise MAT (ignoring 0% MAT) | Qualify (Y/N) Y=Yes N=No | M3 Price per Unit (Rs.) | Price per Unit (Rs.) Considered |
|-------|-------------------------------|---------------|--------------------------------|----------|-----------|--------|-----------|--------------|-------------------|--|--------------------------------|----------------------------------|---------------------------------------|
| | | | | | | | PTR(Rs.) | MAT(Rs.) | SKU wise MAT % | | | | |
| 1 | 4 DAPA 5 MG TABLET 10 | 4 DAPA | 4 CARE LIFESCIENCE PVT LTD | 5 MG | 10 | TABLET | 60.71 | 25255.36 | 0.00% | 0.00% | N | 6.07 | |
| 2 | GLEDEPA 5 MG TABLET 14 | GLEDEPA | ABBOTT HEALTHCARE PVT. LTD | 5 MG | 14 | TABLET | 544 | | | | | | |
| 3 | GLUJECT 5 MG TABLET 15 | GLUJECT | ABBOTT HEALTHCARE PVT. LTD | 5 MG | 15 | TABLET | 107.14 | | | | | | |
| 4 | DAXIGA 5 MG TABLET 10 | DAXIGA | ACMEDIX PHARMA LLP | 5 MG | 10 | TABLET | 20.71 | 57118.18 | 0.01% | 0.01% | N | 2.07 | |
| 5 | DAPALEX 5 MG TABLET 10 | DAPALEX | AJANTA PHARMA LTD | 5 MG | 10 | TABLET | 100 | 4821700.00 | 0.82% | 0.82% | N | 10.00 | |
| 6 | DAPANTA 5 MG TABLET 10 | DAPANTA | AJANTA PHARMA LTD | 5 MG | 10 | TABLET | 23.4 | 12612.60 | 0.00% | 0.00% | N | 2.34 | |
| 7 | DAPASIS 5 MG TABLET 10 | DAPASIS | AKESSIS PHARMA (P) LTD | 5 MG | 10 | TABLET | 101.22 | 3060996.42 | 0.52% | 0.52% | N | 10.12 | |
| 8 | SWITDAPA 5 MG TABLET 10 | SWITDAPA | AKUMENTIS HEALTHCARE LTD | 5 MG | 10 | TABLET | 42.14 | 1546875.12 | 0.26% | 0.26% | N | 4.21 | |
| 9 | VOAGE 5 MG TABLET 10 | VOAGE | ALEMVIC LTD | 5 MG | 10 | TABLET | 66.5 | 11898896.66 | 2.02% | 2.02% | Y | 6.65 | 6.65 |
| 10 | DAPANORM 5 MG TABLET 10 | DAPANORM | ALKEM LABORATORIES LTD. | 5 MG | 10 | TABLET | 99.29 | 45849044.01 | 7.77% | 7.77% | Y | 9.93 | 9.93 |
| 11 | FLOZIMAX 5 MG TABLET 15 | FLOZIMAX | ALNICHE LIFE SCIENCES PVT.LTD | 5 MG | 15 | TABLET | 103.57 | 214079.19 | 0.04% | 0.04% | N | 8.80 | |
| 12 | DAPAZOL 5 MG TABLET 10 | DAPAZOL | ALTEUS BIOGENICS PVT.LTD. | 5 MG | 10 | TABLET | 70.71 | 98665.74 | 0.02% | 0.02% | N | 7.07 | |
| 13 | DAPRICA 5 MG TABLET 10 | DAPRICA | APRICA HEALTHCARE PVT LTD | 5 MG | 10 | TABLET | 61.71 | 1726773.14 | 0.28% | 0.28% | N | 6.17 | |
| 14 | GLUFLOZIN 5 MG TABLET 15 | GLUFLOZIN | ARISTO PHARMACEUTICALS PVT.LTD | 5 MG | 15 | TABLET | 75 | 5170575.00 | 0.88% | 0.88% | N | 5.00 | |
| 15 | FORXIGA 5 MG TABLET 14 | FORXIGA | ASTRAZENECA PHARMA INDIA LTD | 5 MG | 14 | TABLET | 313.21 | | | | | | |
| 16 | DIABIZ (BLUE) 5 MG TABLET 15 | DIABIZ (BLUE) | BLUE CROSS LABORATORIES LTD | 5 MG | 15 | TABLET | 53.57 | 2147942.72 | -0.36% | 0.36% | N | 3.57 | |
| 17 | DAPASACH 5 MG TABLET 10 | DAPASACH | CIPLA LTD. | 5 MG | 10 | TABLET | 57.14 | 623111.70 | 0.11% | 0.11% | N | 5.71 | |
| 18 | GLIFDAPA 5 MG TABLET 10 | GLIFDAPA | CMR LIFE SCIENCES | 5 MG | 10 | TABLET | 75 | 10725.00 | 0.00% | 0.00% | N | 7.50 | |
| 19 | DAPABITE 5 MG TABLET 10 | DAPABITE | CORONA | 5 MG | 10 | TABLET | 77.79 | 19333363.53 | 3.28% | 3.28% | Y | 7.78 | 7.78 |
| 20 | DAPLO 5 MG TABLET 10 | DAPLO | DR. REDDYS LABORATORIES LTD | 5 MG | 10 | TABLET | 98.22 | 20794273.04 | 3.52% | 3.52% | Y | 9.82 | 9.82 |
| 21 | ESGEDAP 5 MG TABLET 14 | ESGEDAP | EAST WEST PHARMA | 5 MG | 14 | TABLET | 100 | 279900.00 | 0.05% | 0.05% | N | 7.14 | |
| 22 | XGLET 5 MG TABLET 10 | XGLET | ELINOR PHARMA | 5 MG | 10 | TABLET | 125 | 2250.00 | 0.00% | 0.00% | N | 12.60 | |
| 23 | DAPAGZA 5 MG TABLET 15 | DAPAGZA | EMCURE PHARMACEUTICALS LTD | 5 MG | 15 | TABLET | 148.93 | 257648.90 | 0.04% | 0.04% | N | 8.93 | |
| 24 | EMILDAP 5 MG TABLET 15 | EMILDAP | EMCURE PHARMACEUTICALS LTD | 5 MG | 15 | TABLET | 148.93 | 3726526.46 | 0.63% | 0.63% | N | 9.93 | |
| 25 | DAPAZEP 5 MG TABLET 10 | DAPAZEP | ERGOS LIFE SCIENCES | 5 MG | 10 | TABLET | 64.29 | 1542.96 | 0.00% | 0.00% | N | 6.43 | |
| 26 | GLUXIT 5 MG TABLET 10 | GLUXIT | ERIS LIFESCENCES LTD | 5 MG | 10 | TABLET | 62.86 | 55866983.60 | 9.47% | 9.47% | Y | 6.28 | 6.28 |
| 27 | MYODA 5 MG TABLET 10 | MYODA | ERIS LIFESCENCES LTD | 5 MG | 10 | TABLET | 62.86 | 810006.68 | 0.14% | 0.14% | N | 6.28 | |
| 28 | DIFLUP 5 MG TABLET 10 | DIFLUP | EXELTIS | 5 MG | 10 | TABLET | 106.43 | 292576.07 | 0.05% | 0.05% | N | 10.64 | |

442

| | | | | | | | | | | | | | |
|----|---------------------------|------------|--|------|----|--------|--------|-------------|--------|--------|---|-------|-------|
| 29 | DIABFLOZ 5 MG TABLET 10 | DIABFLOZ | FINECURE PHARMACEUTICALS | 5 MG | 10 | TABLET | 57.15 | 24856.04 | 0.00% | 0.00% | N | 5.72 | |
| 30 | DEXIGLU 5 MG TABLET 10 | DEXIGLU | FUSION HEALTHCARE PVT LTD | 5 MG | 10 | TABLET | 109.29 | 2437118.57 | 0.41% | 0.41% | N | 10.83 | |
| 31 | DAPA GOLD 5 MG TABLET 15 | DAPA GOLD | HBC LIFESCIENCES PVT LTD | 5 MG | 15 | TABLET | 116.79 | 25114054.44 | 4.26% | 4.26% | Y | 7.79 | 7.79 |
| 32 | DAPADOT 5 MG TABLET 10 | DAPADOT | HETERO HEALTHCARE LTD | 5 MG | 10 | TABLET | 77.34 | 182358.96 | 0.03% | 0.03% | N | 7.71 | |
| 33 | DAPARAY 5 MG TABLET 10 | DAPARAY | ICON LIFESCIENCES | 5 MG | 10 | TABLET | 60.71 | 224687.71 | 0.04% | 0.04% | N | 6.07 | |
| 34 | DIMPRIDE 5 MG TABLET 10 | DIMPRIDE | INDICHEMIE HEALTH SPECIALITIES PVT. LTD. | 5 MG | 10 | TABLET | 99.29 | 148438.55 | 0.03% | 0.03% | N | 9.93 | |
| 35 | DEPAJA 5 MG TABLET 10 | DEPAJA | INDOCO REMEDIES LTD | 5 MG | 10 | TABLET | 60.71 | 281633.69 | 0.05% | 0.05% | N | 6.07 | |
| 36 | DAPARYL 5 MG TABLET 10 | DAPARYL | INTAS PHARMACEUTICALS LTD | 5 MG | 10 | TABLET | 77.14 | 45788915.48 | 7.76% | 7.76% | Y | 7.71 | 7.71 |
| 37 | DAPAVEL 5 MG TABLET 10 | DAPAVEL | INTAS PHARMACEUTICALS LTD | 5 MG | 10 | TABLET | 77.14 | 52274229.56 | 8.86% | 8.86% | Y | 7.71 | 7.71 |
| 38 | T2C 5 MG TABLET 15 | T2C | IPCA LABORATORIES PVT LTD. | 5 MG | 15 | TABLET | 160.72 | 3841368.72 | 0.65% | 0.65% | N | 10.71 | |
| 39 | JODAPA 5 MG TABLET 15 | JODAPA | JARUN PHARMACEUTICALS | 5 MG | 15 | TABLET | 96.43 | 105301.56 | 0.02% | 0.02% | N | 6.43 | |
| 40 | DAPACOSE 5 MG TABLET 10 | DAPACOSE | JB CHEMICALS | 5 MG | 10 | TABLET | 78.54 | 9796442.88 | 1.66% | 1.66% | Y | 7.85 | 7.85 |
| 41 | DMBEST 5 MG TABLET 10 | DMBEST | KEPLER HEALTH CARE | 5 MG | 10 | TABLET | 78.57 | 118954.98 | 0.02% | 0.02% | N | 7.86 | |
| 42 | DAPACONIC 5 MG TABLET 15 | DAPACONIC | LA RENON | 5 MG | 15 | TABLET | 138.21 | 282777.66 | 0.05% | 0.05% | N | 9.21 | |
| 43 | DAPAHENZ 5 MG TABLET 10 | DAPAHENZ | LA RENON | 5 MG | 10 | TABLET | 141.43 | 359373.63 | 0.06% | 0.31% | N | 14.14 | |
| 44 | DAPAHENZ 5 MG TABLET 15 | DAPAHENZ | LA RENON | 5 MG | 15 | TABLET | 151.43 | 1486340.13 | 0.25% | 0.31% | N | 10.10 | |
| 45 | DIFOZIN 5 MG TABLET 14 | DIFOZIN | LINCOLN PHARMACEUTICALS LTD | 5 MG | 14 | TABLET | 106.43 | 200088.40 | 0.03% | 0.03% | N | 7.60 | |
| 46 | SUGAFLO 5 MG TABLET 15 | SUGAFLO | LLOYD HEALTHCARE PVT.LTD | 5 MG | 15 | TABLET | 139.29 | 9484952.55 | 1.61% | 1.61% | Y | 9.29 | 9.29 |
| 47 | DAPATURN 5 MG TABLET 10 | DAPATURN | LUPIN LTD | 5 MG | 10 | TABLET | 89.29 | 9980300.46 | 1.69% | 1.69% | Y | 8.93 | 8.93 |
| 48 | DAMITA 5 MG TABLET 10 | DAMITA | MACLEODS PHARMACEUTICALS PVT.LTD | 5 MG | 10 | TABLET | 86.25 | 18151663.23 | 3.08% | 3.08% | Y | 8.83 | 8.83 |
| 49 | DAPAMAC 5 MG TABLET 10 | DAPAMAC | MACLEODS PHARMACEUTICALS PVT.LTD | 5 MG | 10 | TABLET | 86.25 | 36798488.04 | 6.23% | 6.23% | Y | 8.63 | 8.63 |
| 50 | JUSTOZA 5 MG TABLET 10 | JUSTOZA | MANKIND PHARMACEUTICALS LTD. | 5 MG | 10 | TABLET | 53.57 | 9092007.54 | 1.54% | 1.69% | Y | 5.36 | 5.36 |
| 51 | JUSTOZA 5 MG TABLET 15 | JUSTOZA | MANKIND PHARMACEUTICALS LTD. | 5 MG | 15 | TABLET | 80.36 | 863628.92 | 0.15% | 1.69% | Y | 5.36 | 5.36 |
| 52 | SGLTD 5 MG TABLET 10 | SGLTD | MANKIND PHARMACEUTICALS LTD. | 5 MG | 10 | TABLET | 53.57 | 7163541.11 | 1.21% | 1.21% | Y | 5.36 | 5.36 |
| 53 | DAPABUS 5 MG TABLET 10 | DAPABUS | MED MANOR ORGANICS PVT LTD. | 5 MG | 10 | TABLET | 67.86 | 43905.42 | 0.01% | 0.01% | N | 6.79 | |
| 54 | DAPANOVA 5 MG TABLET 15 | DAPANOVA | MEDLEY PHARMACEUTICALS | 5 MG | 15 | TABLET | 105.71 | 8018188.67 | 1.36% | 1.36% | Y | 7.05 | 7.05 |
| 55 | DAJIO 5 MG TABLET 10 | DAJIO | MICRO LABS LTD | 5 MG | 10 | TABLET | 70 | 3217690.00 | 0.55% | 0.55% | N | 7.00 | |
| 56 | ZUCAPRIDE 5 MG TABLET 10 | ZUCAPRIDE | MICRO LABS LTD | 5 MG | 10 | TABLET | 70 | 3949960.00 | 0.67% | 0.67% | N | 7.00 | |
| 57 | DAPACONE 5 MG TABLET 10 | DAPACONE | MSN LABORATORIES LTD | 5 MG | 10 | TABLET | 78.57 | 4389863.04 | 0.74% | 0.74% | N | 7.86 | |
| 58 | DAPNAT 5 MG TABLET 10 | DAPNAT | NATCO PHARMA LTD | 5 MG | 10 | TABLET | 63.57 | 389493.39 | 0.07% | 2.89% | Y | 6.38 | 6.38 |
| 59 | DAPNAT 5 MG TABLET 30 | DAPNAT | NATCO PHARMA LTD | 5 MG | 30 | TABLET | 321.43 | 16629823.91 | 2.82% | 2.89% | Y | 10.71 | 10.71 |
| 60 | DAPABEST 5 MG TABLET 10 | DAPABEST | PANACEA BIOTEC LTD | 5 MG | 10 | TABLET | 64.29 | 1324116.84 | 0.22% | 0.22% | N | 6.43 | |
| 61 | DAPAKEY 5 MG TABLET 10 | DAPAKEY | PRECIA PHARMA | 5 MG | 10 | TABLET | 100 | 869600.00 | 0.15% | 0.15% | N | 10.00 | |
| 62 | GLUFOPRIME 5 MG TABLET 10 | GLUFOPRIME | PRIMUS REMEDIES PVT LTD | 5 MG | 10 | TABLET | 89.29 | 753518.31 | 0.13% | 0.14% | N | 8.93 | |
| 63 | GLUFOPRIME 5 MG TABLET 15 | GLUFOPRIME | PRIMUS REMEDIES PVT LTD | 5 MG | 15 | TABLET | 133.93 | 35759.31 | 0.01% | 0.14% | N | 8.93 | |
| 64 | DPD 5 MG TABLET 10 | DPO | RPG LIFE SCIENCES LTD. | 5 MG | 10 | TABLET | 57.14 | 204846.90 | 0.03% | 0.03% | N | 5.71 | |
| 65 | DAPASAN 5 MG TABLET 14 | DAPASAN | SANATRA HEALTH CARE PVT.LTD | 5 MG | 14 | TABLET | 110 | 21450.00 | 0.00% | 0.00% | N | 7.88 | |
| 66 | SHIDAPA 5 MG TABLET 10 | SHIDAPA | SHINE PHARMACEUTICALS LTD | 5 MG | 10 | TABLET | 53.57 | 12160.39 | 0.00% | 0.00% | N | 5.38 | |
| 67 | DAPAGREAT 5 MG TABLET 15 | DAPAGREAT | SINSAN PHARMACEUTICALS | 5 MG | 15 | TABLET | 135 | 131490.00 | 0.02% | 0.02% | N | 9.00 | |
| 68 | MDAPA 5 5 MG TABLET 10 | MDAPA 5 | SINSAN-PHARMACEUTICALS | 5 MG | 10 | TABLET | 75 | 285675.00 | 0.05% | 0.05% | N | 7.50 | |
| 69 | SINXIGA 5 5 MG TABLET 10 | SINXIGA 5 | SINSAN PHARMACEUTICALS | 5 MG | 10 | TABLET | 75 | 3525.00 | 0.00% | 0.00% | N | 7.50 | |
| 70 | DAPASPEC 5 MG TABLET 10 | DAPASPEC | SPECTRA THERAPEUTICS PVT. LTD. | 5 MG | 10 | TABLET | 57.15 | 457728.51 | 0.08% | 0.08% | N | 5.72 | |
| 71 | DAPEFY 5 MG TABLET 14 | DAPEFY | SUN PHARMA LABORATORIES LTD. | 5 MG | 14 | TABLET | 98 | | | | | | |
| 72 | OXRA 5 MG TABLET 14 | OXRA | SUN PHARMA LABORATORIES LTD. | 5 MG | 14 | TABLET | 98 | | | | | | |
| 73 | DAPAGAIN 5 MG TABLET 15 | DAPAGAIN | SYSTOPIC LABORATORIES LTD-MEM | 5 MG | 15 | TABLET | 41.79 | 6722046.87 | 1.14% | 1.14% | Y | 2.79 | 2.79 |
| 74 | DAPIXA 5 MG TABLET 10 | DAPIXA | TAS MED (INDIA) PRIVATE LTD. | 5 MG | 10 | TABLET | 70.71 | 70215.03 | 0.01% | 0.01% | N | 7.07 | |
| 75 | GLUCRETA 5 MG TABLET 10 | GLUCRETA | TORRENT PHARMACEUTICALS LTD. | 5 MG | 10 | TABLET | 57.29 | 15234140.60 | 2.58% | 2.58% | Y | 5.73 | 5.73 |
| 76 | DGSON 5 MG TABLET 10 | DGSON | UNISON PHARMACEUTICALS | 5 MG | 10 | TABLET | 20.71 | 879491.57 | 0.16% | 0.15% | N | 2.07 | |
| 77 | UDAPA 5 MG TABLET 10 | UDAPA | USV PVT LTD | 5 MG | 10 | TABLET | 90.36 | 81701546.10 | 13.84% | 13.84% | Y | 9.04 | 9.04 |
| 78 | DAPAVAS 5 MG TABLET 10 | DAPAVAS | VASU ORGANICS PVT.LTD | 5 MG | 10 | TABLET | 70.71 | 35213.58 | 0.01% | 0.01% | N | 7.07 | |
| 79 | DIUTEN 5 MG TABLET 10 | DIUTEN | WOCKHARDY LTD | 5 MG | 10 | TABLET | 70.72 | 19940.25 | 0.00% | 0.00% | N | 7.07 | |
| 80 | ZINODAP 5 MG TABLET 10 | ZINODAP | WOCKHARDY LTD | 5 MG | 10 | TABLET | 77.51 | 1956177.22 | 0.33% | 0.33% | N | 7.76 | |
| 81 | DAPAXIGA 5 MG TABLET 14 | DAPAXIGA | ZERICO LIFESCIENCES PVT.LTD | 5 MG | 14 | TABLET | 100 | 2900.00 | 0.00% | 0.00% | N | 7.14 | |
| 82 | DAPAGLYN 5 MG TABLET 15 | DAPAGLYN | ZYDUS CADILA - ZHL | 5 MG | 15 | TABLET | 165 | 30014955.00 | 5.09% | 5.09% | Y | 11.00 | 11.00 |

| | | | | | | | | | | | | | |
|--|-------------------------|----------------|---------------|--|--|--|--|--|--|--|--|--|--|
| | | Rs. Per Tablet | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | Worked out Retail Price | 0.86 | Excluding GST | | | | | | | | | | |

Computation of Retail Price based on January, 2023 Data under Para 5 of DPCO, 2013

Subject: Retail price fixation under Para 5 of DPCO, 2013 – Each film coated bilayered tablet contains: Sitagliptin

| | | |
|--|--|--------|
| Number of Companies consisting of Market Share of 1% & Above | | 19 |
| Sum of MAT value considered for price calculation (In Lakhs) | | 892.65 |
| Sum of PTR per unit considered for price calculation | | 164.96 |
| Number of Packs considered | | 24 |
| Average PTR | | 8.87 |
| Add : 16% Retailer Margin | | 1.10 |
| Retail Price (without local taxes) | | 7.87 |
| % Reduction with compared to Highest Price | | 31.23% |

| | |
|---------------------------------|------|
| Minimum Price (Rs.) | 4.28 |
| Maximum Price (Rs.) | 9.99 |
| Average of all considered (Rs.) | 8.87 |
| Retail Price (Rs.) | 7.97 |

| S.No. | पैक विवरण Pack Description | ब्रांड BRAND | कंपनी Company | Strength | Pack Size | Unit | TOTAL MAT | 10,77,95,359 | 100% | Brandwise MAT (ignoring 0% MAT) | Qualify (Y/N) Y=Yes N=No | M3 Price par Unit (Rs.) | Price per Unit (Rs.) Considered |
|-------|-------------------------------|-----------------|--|----------|-----------|--------|-----------|--------------|-------------------|--|--------------------------------|----------------------------------|---------------------------------------|
| | | | | | | | PTR(Rs.) | MAT(Rs.) | SKU wise MAT % | | | | |
| 1 | SIAGLIDE 50 MG TABLET 15 | SIAGLIDE | ABBOTT HEALTHCARE PVT. LTD | 50 MG | 15 | TABLET | 141.43 | 1347969.33 | 1.25% | 1.25% | Y | 9.43 | 9.43 |
| 2 | ACSITA 50 MG TABLET 10 | ACSITA | ACMEDIX PHARMA LLP | 50 MG | 10 | TABLET | 27.86 | 33682.74 | 0.03% | 0.03% | N | 2.79 | 2.79 |
| 3 | SITAMAX 50 MG TABLET 10 | SITAMAX | AJANTA PHARMA LTD | 50 MG | 10 | TABLET | 85.71 | 736848.87 | 0.68% | 0.68% | N | 8.57 | 8.57 |
| 4 | SITAPAZ 50 MG TABLET 10 | SITAPAZ | AKESSIS PHARMA (P) LTD | 50 MG | 10 | TABLET | 70.72 | 619648.64 | 0.57% | 0.57% | N | 7.07 | 7.07 |
| 5 | SITALEMBIC 50 MG TABLET 15 | SITALEMBIC | ALEMBIC LTD | 50 MG | 15 | TABLET | 96.43 | 2635528.33 | 2.44% | 2.44% | Y | 6.43 | 6.43 |
| 6 | ALSITA 50 MG TABLET 10 | ALSITA | ALKEM LABORATORIES LTD. | 50 MG | 10 | TABLET | 55 | 5866135.00 | 5.44% | 5.44% | Y | 5.60 | 5.60 |
| 7 | SITALONG 50 MG TABLET 15 | SITALONG | ALTEUS BIOGENICS PVT.LTD. | 50 MG | 15 | TABLET | 117.86 | 245738.10 | 0.23% | 0.23% | N | 7.88 | 7.88 |
| 8 | SITAGLIP 50 MG TABLET 10 | SITAGLIP | ANTRIEM BIOPHARMA PVT LTD | 50 MG | 10 | TABLET | 92.86 | 66209.18 | 0.06% | 0.06% | N | 9.29 | 9.29 |
| 9 | SIDIA 50 MG TABLET 10 | SIDIA | APRICA HEALTHCARE PVT LTD | 50 MG | 10 | TABLET | 71.43 | 142431.42 | 0.13% | 0.13% | N | 7.14 | 7.14 |
| 10 | SITAGLO 50 MG TABLET 15 | SITAGLO | ARISTO PHARMACEUTICALS PVT.LTD | 50 MG | 15 | TABLET | 106.07 | 3791472.15 | 3.52% | 3.52% | Y | 7.07 | 7.07 |
| 11 | TERGRA 50 MG TABLET 10 | TERGRA | BIOCIN LTD | 50 MG | 10 | TABLET | 78.57 | 206796.24 | 0.19% | 0.19% | N | 7.86 | 7.86 |
| 12 | JANKEY 50 MG TABLET 15 | JANKEY | CADILA PHARMACEUTICALS LTD | 50 MG | 15 | TABLET | 96.43 | 336347.84 | 0.31% | 0.31% | N | 6.43 | 6.43 |
| 13 | SITENALI 50 MG TABLET 15 | SITENALI | CADILA PHARMACEUTICALS LTD | 50 MG | 15 | TABLET | 95.43 | 212049.57 | 0.20% | 0.20% | N | 6.43 | 6.43 |
| 14 | SITACIP 50 MG TABLET 10 | SITACIP | CIPLA LTD. | 50 MG | 10 | TABLET | 63.57 | 2700932.38 | 2.51% | 2.51% | Y | 6.36 | 6.36 |
| 15 | SITABITE 50 MG TABLET 10 | SITABITE | CORONA | 50 MG | 10 | TABLET | 56.43 | 4345279.29 | 4.03% | 4.03% | Y | 5.64 | 5.64 |
| 16 | STIG 50 MG TABLET 15 | STIG | DR. REDDYS LABORATORIES LTD | 50 MG | 15 | TABLET | 75 | 1695225.00 | 1.57% | 1.57% | Y | 5.00 | 5.00 |
| 17 | EMSITA 50 MG TABLET 10 | EMSITA | EMCURE PHARMACEUTICALS LTD | 50 MG | 10 | TABLET | 99.93 | 2922352.92 | 2.71% | 2.71% | Y | 9.99 | 9.99 |
| 18 | GLURA 50 MG TABLET 10 | GLURA | ERIS LIFESCIENCES LTD | 50 MG | 10 | TABLET | 71.43 | 4373016.03 | 4.06% | 4.06% | Y | 7.14 | 7.14 |
| 19 | SITDC 50 MG TABLET 10 | SITDC | FDC LTD. | 50 MG | 10 | TABLET | 67.14 | 154824.84 | 0.14% | 0.14% | N | 6.71 | 6.71 |
| 20 | CTASORIN 50 MG TABLET 10 | CTASORIN | FUSION HEALTHCARE PVT LTD | 50 MG | 10 | TABLET | 70.71 | 306103.59 | 0.28% | 0.28% | N | 7.07 | 7.07 |
| 21 | SITAZIT 50 MG TABLET 10 | SITAZIT | GLENMARK PHARMACEUTICALS LTD. | 50 MG | 10 | TABLET | 75 | 4394325.00 | 4.08% | 4.08% | Y | 7.50 | 7.50 |
| 22 | QSITA 50 MG TABLET 10 | QSITA | HBC LIFESCIENCES PVT LTD | 50 MG | 10 | TABLET | 57.34 | 805559.72 | 0.75% | 0.75% | N | 5.71 | 5.71 |
| 23 | SITOZA 50 MG TABLET 10 | SITOZA | HETERO HEALTHCARE LTD | 50 MG | 10 | TABLET | 64.29 | 136658.22 | 0.13% | 0.13% | N | 6.43 | 6.43 |
| 24 | SPIKERID 50 MG TABLET 10 | SPIKERID | INDICHEMIE HEALTH SPECIALITIES PVT. LTD. | 50 MG | 10 | TABLET | 55 | 21285.00 | 0.02% | 0.02% | N | 5.50 | 5.50 |
| 25 | IGNALIS 50 MG TABLET 10 | IGNALIS | INTAS PHARMACEUTICALS LTD | 50 MG | 10 | TABLET | 64.29 | 4574169.21 | 4.24% | 4.24% | Y | 6.43 | 6.43 |
| 26 | SITARA 50 MG TABLET 10 | SITARA | INTAS PHARMACEUTICALS LTD | 50 MG | 10 | TABLET | 64.29 | 6348251.76 | 5.89% | 5.89% | Y | 6.43 | 6.43 |
| 27 | SUITGLIP 50 MG TABLET 10 | SUITGLIP | IPCA LABORATORIES PVT LTD. | 50 MG | 10 | TABLET | 60.72 | 127572.72 | 0.12% | 0.12% | N | 6.07 | 6.07 |
| 28 | SITACOSE 50 MG TABLET 10 | SITACOSE | JB CHEMICALS | 50 MG | 10 | TABLET | 78.58 | 118891.54 | 0.11% | 0.11% | N | 7.86 | 7.86 |
| 29 | SITAHENZ 50 MG TABLET 10 | SITAHENZ | LA RENON | 50 MG | 10 | TABLET | 70 | 4458650.00 | 4.14% | 4.14% | Y | 7.00 | 7.00 |
| 30 | SUGARAY 50 MG TABLET 15 | SUGARAY | LLOYD HEALTHCARE PVT.LTD | 50 MG | 15 | TABLET | 106.08 | 989726.40 | 0.92% | 0.92% | N | 7.07 | 7.07 |

| | | | | | | | | | | | | | |
|----|----------------------------|----------------|------------------------------------|-------|----|--------|--------|------------|-------|-------|---|-------|-------|
| 31 | LUPISIT 50 MG TABLET 10 | LUPISIT | LUPIN LTD | 50 MG | 10 | TABLET | 78.57 | 6701471.01 | 6.22% | 6.22% | Y | 7.86 | 7.86 |
| 32 | MACSITA 50 MG TABLET 10 | MACSITA | MACLEODS PHARMACEUTICALS PVT.LTD | 50 MG | 10 | TABLET | 62.86 | 3220569.24 | 2.99% | 2.99% | Y | 8.29 | 8.29 |
| 33 | SITA OD 50 MG TABLET 10 | SITA OD | MACLEODS PHARMACEUTICALS PVT.LTD | 50 MG | 10 | TABLET | 62.86 | 4484935.28 | 4.16% | 4.16% | Y | 6.29 | 6.29 |
| 34 | SITACCLASS 50 MG TABLET 10 | SITACCLASS | MACLEODS PHARMACEUTICALS PVT.LTD | 50 MG | 10 | TABLET | 62.86 | 112205.10 | 0.10% | 0.10% | N | 6.29 | 6.29 |
| 35 | SITADAY 50 MG TABLET 15 | SITADAY | MANKIND PHARMACEUTICALS LTD. | 50 MG | 15 | TABLET | 96.32 | 3965109.12 | 3.68% | 3.68% | Y | 6.42 | 6.42 |
| 36 | CORSITA 50 MG TABLET 10 | CORSITA | MEDLEY PHARMACEUTICALS | 50 MG | 10 | TABLET | 63.57 | 687753.83 | 0.64% | 0.64% | N | 6.36 | 6.36 |
| 37 | JOGSITA 50 MG TABLET 10 | JOGSITA | MEDOPHARM | 50 MG | 10 | TABLET | 75 | 2775.00 | 0.00% | 0.00% | N | 7.50 | 7.50 |
| 38 | SITANORM 50 MG TABLET 15 | SITANORM | MICRO LABS LTD | 50 MG | 15 | TABLET | 95.71 | 2608863.18 | 2.42% | 2.42% | Y | 6.38 | 6.38 |
| 39 | SITAPRIDE 50 MG TABLET 15 | SITAPRIDE | MICRO LABS LTD | 50 MG | 15 | TABLET | 95.71 | 2826794.85 | 2.62% | 2.62% | Y | 6.38 | 6.38 |
| 40 | JANUVIA 50 MG TABLET 7 | JANUVIA | MSD PHARMACEUTICALS PRIVATE LTD. | 50 MG | 7 | TABLET | 189.29 | | | | | | |
| 41 | SITA (MSN) 50 MG TABLET 10 | SITA (MSN) | MSN LABORATORIES LTD | 50 MG | 10 | TABLET | 67.86 | 139723.74 | 0.13% | 0.13% | N | 6.79 | 6.79 |
| 42 | SITANAT 50 MG TABLET 10 | SITANAT | NATCO PHARMA LTD | 50 MG | 10 | TABLET | 92.14 | 594947.98 | 0.55% | 0.55% | N | 8.21 | 8.21 |
| 43 | GLUPCRIN 50 MG TABLET 15 | GLUPCRIN | PRIMUS REMEDIES PVT LTD | 50 MG | 15 | TABLET | 128.57 | 343539.04 | 0.32% | 0.32% | N | 8.57 | 8.57 |
| 44 | 6F1C 50 MG TABLET 15 | 6F1C | SINSAN PHARMACEUTICALS | 50 MG | 15 | TABLET | 150 | 192600.00 | 0.18% | 0.18% | N | 10.00 | 10.00 |
| 45 | ISTAVEL 50 MG TABLET 7 | ISTAVEL | SUN PHARMA LABORATORIES LTD. | 50 MG | 7 | TABLET | 42.5 | | | | | | |
| 46 | SITARED 50 MG TABLET 7 | SITARED | SUN PHARMA LABORATORIES LTD. | 50 MG | 7 | TABLET | 42.5 | | | | | | |
| 47 | SITALENT 50 MG TABLET 10 | SITALENT | TALENT INDIA | 50 MG | 10 | TABLET | 70.72 | 244479.04 | 0.23% | 0.23% | N | 7.07 | 7.07 |
| 48 | ZYSITA 50 MG TABLET 7 | ZYSITA | THREE DOTS UFESCIENCE | 50 MG | 7 | TABLET | 75 | 7050.00 | 0.01% | 0.01% | N | 10.71 | 10.71 |
| 49 | SITAXA 50 MG TABLET 15 | SITAXA | TORRENT PHARMACEUTICALS LTD. | 50 MG | 15 | TABLET | 127.5 | 7786170.00 | 7.22% | 7.22% | Y | 8.50 | 8.50 |
| 50 | STALIX 50 MG TABLET 15 | STALIX | TORRENT PHARMACEUTICALS LTD. | 50 MG | 15 | TABLET | 127.5 | 7127505.00 | 6.61% | 6.61% | Y | 8.50 | 8.50 |
| 51 | SITASON 50 MG TABLET 10 | SITASON | UNISON PHARMACEUTICALS | 50 MG | 10 | TABLET | 25 | 149175.00 | 0.14% | 0.14% | N | 2.50 | 2.50 |
| 52 | SITAWOK 50 MG TABLET 15 | SITAWOK | WOCKHARDT LTD | 50 MG | 15 | TABLET | 64.19 | 2557329.60 | 2.37% | 2.37% | Y | 4.28 | 4.28 |
| 53 | SITASAR 50 MG TABLET 10 | SITASAR | WONSET HEALTH CARE PRIVATE LIMITED | 50 MG | 10 | TABLET | 64.28 | 16135.10 | 0.01% | 0.01% | N | 6.43 | 6.43 |
| 54 | ZENSITA 50 MG TABLET 10 | ZENSITA | ZUVENTUS HEALTHCARE LTD | 50 MG | 10 | TABLET | 60.71 | 779819.95 | 0.72% | 0.72% | N | 6.07 | 6.07 |
| 55 | SIGLYN 50 MG TABLET 10 | SIGLYN | ZYDUS CADILA - ZHL | 50 MG | 10 | TABLET | 70.71 | 4801491.84 | 4.45% | 4.45% | Y | 7.07 | 7.07 |
| 56 | SITAGLYN 50 MG TABLET 10 | SITAGLYN | ZYDUS CADILA - ZHL | 50 MG | 10 | TABLET | 70.71 | 3731225.28 | 3.46% | 3.46% | Y | 7.07 | 7.07 |
| | | Rs. Per Tablet | | | | | | | | | | | |
| | Worked out Retail Price | 7.97 | Excluding GST | | | | | | | | | | |